PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

18th Congress of EHA

13-16 June 2013 STOCKHOLM

N. Poster

Poster title

Applicant name

Status


3-P	NOVEL COPY NUMBER ALTERATIONS IN INFANTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL)	Marcela B. Mansur	Received

6-P	ACUTE LYMPHOBLASTIC LEUKEMIA RECOGNITION BY NATURAL KILLER CELLS: CLINICAL AND THERAPEUTIC IMPLICATIONS	Nadia Peragine	Received

7-P	K-RASG12D-initiated T-ALL development in mice is accompanied by loss of the wild-type Kras allele	Anna Staffas	Received

8-P	FREQUENCY AND PROGNOSTIC SIGNIFICANCE OF COPY NUMBER ALTERATIONS (CNA) IN HIGH-RISK B-LINEAGE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS ENROLLED IN RISK-ADAPTED PROTOCOLS	Jordi Ribera	Received

9-P	P38ALPHA/BETA INHIBITION PREVENTS ALL PROLIFERATION IN VIVO	Denis Schewe	Received

12-P	ANALYSIS OF CRLF2 EXPRESSION IN A COHORT OF 91 NEWLY DIAGNOSED ADULT PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: CORRELATION WITH CLINICO-BIOLOGICAL FEATURES AND OUTCOME	Fulvia Brugnoletti	Received

13-P	A CLINICALLY RELEVANT POPULATION OF LEUKEMIC CD34CD19CD58- CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Yuan Kong	Received

17-P	ETV6/RUNX1 TRANSCRIPT IS A POTENTIAL TARGET OF RNA-BINDING PROTEIN IGF2BP1	Mindaugas Stoskus	Received

18-P	SNP ARRAY ANALYSIS OF ADULT ALL: A POPULATION BASED STUDY OF LITHUANIAN PATIENTS	Vaidas Dirse	Received

22-P	PML/RAR-ALPHA INHIBITS PTEN EXPRESSION IN HEMATOPOIETIC CELLS BY COMPETING WITH PU.1 TRANSCRIPTIONAL ACTIVITY	Nelida Ines Ngguera	Received

26-P	THE GENE SIGNATURE IN C/EBPA DYSFUNCTIONAL AML PREDICTS RESPONSIVENESS TO HDAC INHIBITORS	Meritxell Alberich Jorda	Received

29-P	THE EFFECT OF ARA-C TREATMENT ON HEMATOPOIETIC STEM CELL EXPANSION AND LEUKEMOGENESIS IN A MOUSE MODEL OF CEBPA MUTANT ACUTE MYELOID LEUKEMIA	monica cimino	Received

32-P	C/EBPA REGULATES CXCR4 EXPRESSION IN ACUTE MYELOID LEUKEMIA	Yuan-Yeh Kuo	Received

33-P	COMBINED INHIBITION OF C-KIT AND PI3K/MTOR SIGNALLING HAS SYNERGISTIC ACTIVITY IN C-KIT MUTANT AML	Steven Tinsley	Received

34-P	THE FUSION GENE NUP98-HOXA9 AS A MODEL FOR LEUKEMOGENESIS: EXPLORING ITS MOLECULAR MECHANISMS AND FUNCTIONAL EFFECTS	ANA RIO-MACHIN	Received

35-P	ACID CERAMIDASE PROMOTES ACUTE MYELOID LEUKEMIA SURVIVAL THROUGH MCL-1 UPREGULATION	Su-Fern Tan	Received

36-P	ANTILEUKEMIC EFFECT OF PI3K-MTOR INHIBITORS IN ACUTE MYELOID LEUKEMIA- GENE EXPRESSION PROFILES REVEAL CDC25B EXPRESSION AS DETERMINATE OF PHARMACOLOGICAL EFFECT	Hkon Reikvam	Received

37-P	L-ASPARAGINASE ALTERS TRANSCRIPTION AND TRANSLATION OF GENES INVOLVED IN METABOLISM IN MYELOID LEUKEMIA	Sung Ah Jun	Received

38-P	THE TYROSINE KINASE CSK ASSOCIATES WITH FLT3 AND KIT RECEPTORS AND REGULATES DOWNSTREAM SIGNALING IN ACUTE MYELOID LEUKEMIA	Julhash Kazi	Received

39-P	WHOLE GENOME AND TARGETED BISULFITE SEQUENCING REVEALS 3 DNA METHYLATION CLUSTERS AND NEW BIOLOGICALLY RELEVANT HYPERMETHYLATED GENES IN AML PATIENTS	Hana Hajkova	Received

40-P	EXPRESSION OF THE SPLICE VARIANT NPM1-R2 HAS STRONGER PROGNOSTIC VALUE THAN NPM1 MUTATIONAL STATUS IN ACUTE MYELOID LEUKEMIA	Malgorzata Zajac	Received

49-P	EX VIVO PHARMACOLOGICAL EVALUATION OF 16 DRUGS IN 60 ACUTE MYELOID LEUKEMIA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY	Belén Liébana	Received

50-P	SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTI-CD33 ANTIBODY TREATMENT IN AML GEMTUZUMAB OZOGAMACIN HAS ANTI-LEUKAEMIC EFFICACY	Ching Loke	Received

51-P	RISK-ADAPTED TRANSPLANT SELECTION ATTENUATES THE NEGATIVE PROGNOSTIC ROLE OF MINIMAL RESIDUAL DISEASE AND GENETIC HIGH RISK FEATURES	Francesco Buccisano	Received

53-P	ELACYTARABINE / IDARUBICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO FAILED CYTARABINE BASED INDUCTION, AND EVALUATION OF THE IMPACT OF THE TRANSPORTER HENT1 ON RESPONSE; RESULTS OF A PHASE II STUDY	Malin Johansen	Received

56-P	PATTERNS OF RELAPSE IN 169 PATIENTS TREATED WITH ORAL ARSENIC TRIOXIDE DURING INDUCTION AND/OR MAINTENANCE: A 12-YEAR EXPERIENCE	Harinder Gill	Received

57-P	SURVIVAL IMPACT OF COMPLEX AND MONOSOMAL KARYOTYPE AND LOSS OF CHROMOSOMES 5, 7 AND 17 IN OLDER PATIENTS WITH AML. FIRST EVALUATION OF CYTOGENETIC DATA FROM THE POPULATION BASED SWEDISH AML REGISTRY	Vladimir Lazarevic	Received

58-P	PATIENTS WITH LATE RELAPSE OF ACUTE MYELOID LEUKEMIA HAVE A HIGH RATE OF DURABLE SECOND COMPLETE REMISSIONS WHEN TREATED WITH CHEMOTHERAPY ONLY	sa Derolf	Received

59-P	SURVIVAL IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN GERMANY AND THE UNITED STATES: UNEXPLAINED DIFFERENCES IN SURVIVAL IN YOUNG ADULTS	Dianne Pulte	Received

61-P	LOW- DOSE CHEMOTHERAPY AND DIFFERENTIATING AGENTS AS POST- REMISSION MAINTENANCE PROLONGED DISEASE- FREE AND OVERALL SURVIVAL IN A CASE-CONTROL RETROSPECTIVE STUDY ON POOR PROGNOSIS AML/MDS PATIENTS	Crisà Elena	Received

62-P	A STUDY OF ELACYTARABINE IN RELAPSED OR REFRACTORY AML EVALUATING CARDIAC SAFETY AND PHARMACOKINETIC PROPERTIES	Malin Johansen	Received

63-P	MULTI-LINEAGE DYSPLASIA AS ASSESSED BY IMMUNO-PHENOTYPE HAS NO IMPACT ON OUTCOME OF ACUTE MYELOID LEUKEMIA WITH MUTATED NUCLEOPHOSMIN (NPM1)	Francesco Mannelli	Received

65-P	MEDIUM-SIZED FLT3 INTERNAL TANDEM DUPLICATIONS CONFER WORSE PROGNOSIS, THAN SHORT AND LONG DUPLICATIONS	Magdalena Koszarska	Received

67-P	THERAPY-RELATED MYELOID NEOPLASMS: REPORT OF THE ITALIAN NETWORK ON SECONDARY LEUKEMIAS	LUANA FIANCHI	Received

68-P	AZACITIDINE FOR RELAPSE TREATMENT IN MYELOID MALIGNANCIES FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	Benoit Tessoulin	Received

69-P	MONITORING MINIMAL RESIDUAL DISEASE IN NPM-1 MUTATED ACUTE MYELOID LEUKEMIA. PRELIMINARY RESULTS AT A SINGLE INSTITUTION	Chiara Pagani	Received

70-P	THE PROGNOSTIC IMPACT OF ADDITIONAL KARYOTYPIC ABNORMALITIES IN T(8;21) ACUTE MYELOID LEUKEMIA	Zhentang Lao	Received

71-P	BAALC GENE EXPRESSION REDUCTION DURING INDUCTION PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA	vanessa ponziani	Received

74-P	SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA	alessandra malato	Received

75-P	ACHIEVING BONE MARROW CLL MINIMAL RESIDUAL DISEASE-FREE STATUS WITH FIRST-LINE FCR IS ASSOCIATED WITH IMPROVED PFS AND CAN BE CONSIDERED A PRIMARY TREATMENT OBJECTIVE	PAOLO STRATI	Received

76-P	DEVELOPMENT OF A COMPREHENSIVE PROGNOSTIC INDEX PATIENTS WITH CLL	Natali Pflug	Received

78-P	CHRONIC LYMPHOCYTIC LEUKEMIA CELLS FROM PAIRED LYMPH NODE AND PERIPHERAL BLOOD SHOW A DIFFERENT PATTERN OF COPY NUMBER ABERRATIONS	Silvia Bonina	Received

80-P	A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT (TFT) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	JOSE-ANGEL HERNANDEZ	Received

81-P	NOTCH1 MUTATED IGHV UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CONSTITUTIVELY OVEREXPRESSED NUCLEOPHOSMIN-1 AND RIBOSOME-ASSOCIATED COMPONENTS	Michele Dal Bo	Received

82-P	CLL: DIFFERENT AGES, DIFFERENT ANTIGEN RECEPTOR PROFILES	PANAGIOTIS BALIAKAS	Received

83-P	DETECTION OF TP53 DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA BY AN IN VITRO FUNCTIONAL ASSAY BASED ON TP53 ACTIVATION BY THE NON-GENOTOXIC DRUG NUTLIN-3: A PROPOSAL FOR CLINICAL APPLICATION	Federico Pozzo	Received

85-P	SEQUENTIAL MRD ANALYSIS IN CLL DEMONSTRATES EXPONENTIAL EXPANSION WITH A PATTERN THAT CANNOT BE PREDICTED FROM PRE-TREATMENT DOUBLING TIME.	Andy Rawstron	Received

87-P	UNRAVELING THE HETEROGENEITY OF T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)	Anton W. Langerak	Received

88-P	EPIGENETIC INACTIVATION OF MIR-34B/C IN ADDITION TO MIR-34A AND DAPK1 IN CHRONIC LYMPHOCYTIC LEUKEMIA	Luqian WANG	Received

91-P	BIALLELIC LOSSES OF 13Q DO NOT CONFER A POORER OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF 627 PATIENTS WITH ISOLATED 13Q DELETION.	Anna Puiggros	Received

92-P	A HIGH SENSITIVITY METHOD REVEALED A TWOFOLD-INCREASED INCIDENCE OF NOTCH1 MUTATION WITH ADVERSE PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKAEMIA	paolo sportoletti	Received

94-P	NOVEL ASSAY FOR THE IDENTIFICATION OF NOTCH1 PEST DOMAIN MUTATIONS USING FRAGMENT ANALYSIS AND ALLELE SPECIFIC PCR	Paulo Campregher	Received

95-P	LONG-LASTING RESPONSES TO LENALIDOMIDE AS INITIAL THERAPY OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	PAOLO STRATI	Received

96-P	LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP	Luká Smolej	Received

97-P	PLATINUM AND HIGH-DOSE CYTARABINE-BASED CHEMOTHERAPY IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTERS SYNDROME: RESULTS OF A RETROSPECTIVE MULTICENTER STUDY	Eric DUROT	Received

99-P	TOXICITY AND RESPONSE BY COMORBIDITY AND AGE IN A RANDOMIZED STUDY OF ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE WITH RITUXIMAB FIRST-LINE THERAPY OF FIT ELDERLY WITH CHRONIC LYMPHOCYTIC LEUKAEMIA	Stephen Mulligan	Received

101-P	PRELIMINARY RESULTS FROM A SURVEY OF REAL-LIFE FIRST LINE THERAPY OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE UK	Tony Todd	Received

103-P	INCREASED EXPRESSION OF THE EZH2 METHYLTRANSFERASE AND EVIDENCE OF FUNCTIONALITY IN CLL SUBGOUPS WITH AGGRESSIVE CLINICOBIOLOGICAL PROFILES	Nikos Papakonstantinou	Received

104-P	OUTCOMES OF PATIENTS WITH FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) A POPULATION-BASED STUDY FROM A WELL-DEFINED GEOGRAPHIC REGION	Sandra Eketorp Sylvan	Received

105-P	PROLONGED CYTOPENIA RELATED TO FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA	PAOLO STRATI	Received

106-P	FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DELETION 17P	PAOLO STRATI	Received

108-P	UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.	Miguel Piris-Villaespesa	Received

110-P	THE PROGNOSTIC VALUE OF THE NUMBER OF CELLS WITH A DELETION OF 13Q14 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Ekaterina Zotina	Received

113-P	IMATINIB OR DASATINIB TREATMENT OF CHRONIC MYELOID LEUKEMIA REDUCES CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AND INCREASES THEIR CD40 EXPRESSION	Stina Sderlund	Received

114-P	THE AXIS SHP-1/SHP-2 MODULATES VEGFR2 SIGNALING IN CML CELL LINES: VEGFR2 DEREGULATION MAY BE IMPLICATED IN IMATINIB (IMA) RESISTANCE	Nicola Esposito	Received

115-P	SYNERGY BETWEEN JAK INHIBITOR RUXOLITINIB AND TYROSINE KINASE INHIBITORS (TKIS) TO OVERCOME DRUG RESISTANCE RELATED TO BONE MARROW (BM) STROMA MICROENVIRONMENT IN CHRONIC MYELOID LEUKEMIA (CML)	Concetta Quintarelli	Received

116-P	CHRONIC MYELOID LEUKEMIA WITH VARIANT T(9;22) REVEALS A DIFFERENT SIGNATURE FROM CASES WITH CLASSIC TRANSLOCATION.	Francesco Albano	Received

118-P	REDUCED EXPRESSION OF CHIBBY IS A COMPONENT OF BETA-CATENIN ACTIVATION IN CHRONIC MYELOID LEUKEMIA STEM CELLS	Elisa Leo	Received

119-P	DIFFERENTIAL ACTIVATION OF MTOR KINASE IN CHRONIC AND BLASTIC PHASE OF CHRONIC MYELOGENOUS LEUKEMIA	Tomasz Stoklosa	Received

120-P	MYELOID-DERIVED SUPPRESSOR CELLS ARE INCREASED IN CHRONIC MYELOID LEUKEMIA AND EXERT IMMUNE SUPPRESSIVE ACTIVITY	Cesarina Giallongo	Received

121-P	CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS	Sung-Eun Lee	Received

122-P	DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED	Caterina De Benedittis	Received

124-P	A NEW NON CANONICAL ROLE OF IKB ALPHA IN CHRONIC MYELOID LEUKEMIA PATHOGENESIS	Cristina Panuzzo	Received

125-P	L-AMINO ACID OXIDASE ISOLATED FROM BOTHROPS PIRAJAI INDUCES APOPTOSIS IN BCR-ABL POSITIVE CELLS AND POTENTIATES IMATINIB MESYLATE EFFECT	sandra burin	Received

126-P	IL-2, IL-12 AND IL-15 PREVENT REACTIVE OXYGEN SPECIES ACCUMULATION ON NATURAL KILLER CELLS FROM CHRONIC MYELOID LEUKEMIA PATIENTS FOLLOWING INTERFERON-ALPHA, IMATINIB AND DASATINIB THERAPY	Paulo Rodrigues Santos	Received

127-P	EFFECT OF NILOTINIB ON THE FUNCTION OF CAROTID ARTERY ENDOTHELIAL CELLS	mr Gkmen Sevindik	Received

128-P	STANDARDIZATION OF MRD DETECTION IN CML BY USE OF A PEER GROUP CONVERSION FACTOR	Els Dumoulin	Received

129-P	BIOLOGICAL CHARACTERISTICS AND DYNAMICS OF BCR-ABL1 MULTIPLE MUTATIONS IN TYROSINE KINASE INHIBITOR RESISTANT CML	Soohyun Kim	Received

131-P	10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML)	CLAIRE LUCAS	Received

132-P	IMPACT OF DRUG TRANSPORTER ABCG2 HAPLOTYPES IN MOLECULAR RESPONSE OF CML PATIENTS IS MODULATED BY IMATINIB DAILY DOSE	delord marc	Received

135-P	FIFTEEN-MONTH UPDATE OF A PHASE II TRIAL OF THE COMBINATION OF PEGYLATED INTERFERON ALPHA2ANILOTINIB AS FIRST LINE THERAPY FOR NEWLY DIAGNOSED CHRONIC PHASE CML PATIENTS	Franck Nicolini	Received

142-P	HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: RESULTS OF A GERMAN CROSS-SECTIONAL STUDY IN PATIENTS PREVIOUSLY REGISTERED IN PROSPECTIVE, CONTROLLED CLINICAL TRIALS	Susanne Sauele	Received

144-P	DISCONTINUATION OF BCR-ABL1 TYROSINE KINASE INHIBITOR IN CML PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE FOR AT LEAST 1 YEAR: INCLUDING UPDATED DATA FROM KIDS STUDY	Yun jeong Oh	Received

146-P	EFFICACY OF NILOTINIB VERSUS HIGH-DOSE IMATINIB IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE SUBOPTIMAL MOLECULAR RESPONSES TO STANDARD-DOSE IMATINIB: MULTICENTER RE-NICE STUDY	Soo Young Choi	Received

147-P	OCT1 GENETIC VARIANTS ARE ASSOCIATED WITH LONG TERM OUTCOMES IN IMATINIB TREATED CML PATIENTS	Maya Koren-Michowitz	Received

150-P	MECHANISM OF IMPAIRED GLUCOSE METABOLISM DURING NILOTINIB THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA	Zdenek Racil	Received

152-P	FLOW CYTOMETRY EARLY DETECTION OF CD4CD26-CD38 LYMPHOCYTES SUBSET IN LYMPH NODES OF HODGKIN LYMPHOMA	Giuseppe Tagariello	Received

153-P	FIRST-LINE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA FINAL RESULTS OF A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS	Michaela Rancea	Received

155-P	A SIMPLE, ACCESSIBLE NEW TOOL TO DEFINE HIGH RISK PATIENTS IN CLASSICAL HODGKIN LYMPHOMA BASED ON VALIDATION OF PRE-EXISTING BIOMARKERS	Paul Greaves	Received

158-P	ESHAP AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY HODGKINS LYMPHOMA	Jorge Labrador	Received

160-P	THE LYMPHOCYTIC HISTOPATHOLOGIC SUBTYPES OF HODGKIN LYMPHOMA (HL): CLINICAL PRESENTATION AND LONG-TERM OUTCOME IN A CASE SERIES OF 61 PATIENTS	Theodoros Vassilakopoulos	Received

161-P	LONG TERM RESULTS OF MONOCENTRIC PROSPECTIVE STUDY OF VEBEP PLUS RADIOTHERAPY REGIMEN IN NEWLY DIAGNOSED EARLY-UNFAVORABLE STAGE HODGKIN LYMPHOMA	SIMONA PAGLIUCA	Received

162-P	DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR PRIMARY REFRACTORY HODGKINS LYMPHOMA TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION	Marianna David	Received

163-P	HETEROGENEOUS MANAGEMENT OF ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA AND INCONSTANT CONFORMITY OF MEDICAL PRACTICE TO CLINICAL GUIDELINES: EXHAUSTIVE COHORT FROM RHNE-ALPES REGION	Arthur Dony	Received

166-P	RECURRENT SETBP1 MUTATIONS IN ATYPICAL CHRONIC MYELOID LEUKEMIA	SARA REDAELLI	Received

168-P	ABERRANT SPLICING DURING ERYTHROID DIFFERENTIATION IN SF3B1 MUTATED SIDEROBLASTIC ANEMIA	Simona Conte	Received

169-P	RESISTANCE TO APOPTOSIS IN HIGH-RISK MYELODYSPLASTIC SYNDROME CAN BE OVERCOME BY PRO-APOPTOTIC DRUG TREATMENT USING ABT-737	Stefanie Jilg	Received

173-P	A PAIR MONOZYGOTIC TWINS WITH CONCORDANT JUVENILE MYELOMONOCYTIC LEUKEMIA: INSIGHT IN THE COURSE OF THE DISEASE	Silvia Bresolin	Received

174-P	FAMILIAL, NON-ZINC FINGER REGION, GATA2 MUTATED MYELODYSPLASTIC SYNDROME; ASSOCIATED WITH SHORTENED TELOMERE LENGTHS, VIRAL WARTS, PROFOUND MONOCYTE/B/NK CELL DEFICIENCY	Mrinal Patnaik	Received

175-P	EVALUATION OF PRO-SURVIVAL PATHWAYS, INCLUDED AUTOPHAGY, IN HIGH-RISK MDS BONE MARROW AFTER TREATMENT WITH 5-AZACITIDINE TO RESTORE NORMAL HEMATOPOIESIS	ALESSANDRA ROMANO	Received

177-P	FLOW CYTOMETRIC CLASSIFICATION OF 350 TYPE III PNH CLONES IN ITALY: A MULTI-CETRIC STUDY	ELISA CANNIZZO	Received

178-P	CYTOGENETIC CHARACTERIZATION OF CD34 HEMATOPOIETIC PROGENITOR CELLS AND MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME (MDS)	Maria Pimenova	Received

179-P	POLYMORPHISMS IN GENES INVOLVED IN DNA REPAIR AND FOLATE PATHWAY SIGNIFICANTLY IMPACT ON SURVIVAL IN LOW-RISK, UNTREATED MYELODYSPLASIA.	Giuseppe Visani	Received

183-P	EVALUATION OF A HIGH THROUGHPUT MUTATION-SCREENING STRATEGY IN MYELODYSPLASTIC SYNDROME PATIENTS AND ACUTE MYELOID LEUKEMIA USING TARGETED-GENE ENRICHMENT TECHNOLOGY	Mohsen Karimi Arzenani	Received

184-P	Impact of 5q Breakpoints on Clinical Outcomes in Patients With IPSS Low/Int-1-Risk Myelodysplastic Syndromes (MDS) and Isolated del(5q) Treated With Lenalidomide in the MDS-004 Study	Gudrun Ghring	Received

185-P	PROGNOSTIC IMPACT OF DER(1;7) IN MDS IS DIFFERENT FROM DEL(7Q)	Julie Schanz	Received

186-P	CLINICAL SIGNIFICANCE OF ASXL1 MUTATION IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROME AND ITS STABILITY DURING DISEASE PROGRESSION	Tsung Chih Chen	Received

188-P	HIGH DOSES OF ELTROMBOPAG ARE WELL-TOLERATED IN CONJUNCTION WITH AZACITIDINE AND THE COMBINATION DEMONSTRATES ENCOURAGING ACTIVITY IN PATIENTS WITH MDS AND AML.	Michael Dickinson	Received

195-P	IMPROVED PREDICTIVE PROGNOSTIC POWER OF REVISED-IPSS (IPSS-R) IN A SERIES OF 301 PATIENTS WITH MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER.	Montserrat Arnan Sangerman	Received

197-P	HIGH LEVELS OF CEREBLON MESSENGER RNA ARE THE CHARACTERISTIC FEATURE OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH 5Q DELETION AND ARE CONNECTED WITH THE EFFICACY OF LENALIDOMIDE	Ota Fuchs	Received

199-P	MORTALITY BURDEN OF TRANSFUSION DEPENDENCY AND IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES.	Montserrat Arnan Sangerman	Received

200-P	NOVEL 3Q26 DELETION BONE MARROW FAILURE SYNDROME IN A NEWBORN RESULTING IN DOMINANT NEGATIVE INTERFERENCE OF HEMATOPOIESIS BY TRUNCATED EVI1/MECOM	Lars van der Veken	Received

202-P	EUROPEAN PATTERN AND IMPACT OF THE USE ERYTHROPOIETIC AGENTS (ESAS)IN LOW AND INT-1 RISK MDS WITH PROPENSITY SCORING TECHNIQUES IN OBSERVATIONAL LONGITUDINAL STUDIES.	Hege Garelius	Received

204-P	ANTI-MYELOMA ACTIVITY OF A NOVEL ALKYLATING AGENT MELPHALAN-FLUFENAMIDE	Dharminder Chauhan	Received

205-P	METABOLOMIC PROFILING IDENTIFIES MECHANISMS REGULATING HYPOXIA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA.	Patricia Maiso	Received

206-P	GENOMIC CHARACTERIZATION OF THE PUTATIVE MULTIPLE MYELOMA STEM CELLS CLONE REVEALS COPY NUMBER ALTERATIONS (CNAS) POSSIBLY CORRELATED WITH THE ORIGIN OF DISEASE	Marina Martello	Received

207-P	MULTIDIMENSIONAL FLOW CYTOMETRY FOR SENSITIVE EVALUATION OF PATIENTS WITH IGM MGUS OR WALDENSTROMS MACROGLOBULINEMIA AND DIFFERENTIAL DIAGNOSIS WITH OTHER LYMPHOMAS	Bruno Paiva	Received

208-P	IDENTIFICATION OF SERUM MICRORNA PROFILE IN MULTIPLE MYELOMA ASSOCIATED WITH COMPLETE REMISSION AND PROGRESSION AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION	Carlos Fernández de Larrea	Received

209-P	IMPROVED ACCURACY OF DISCRIMINATION BETWEEN IGM MULTIPLE MYELOMA (MM) AND WALDENSTROEMS MACROGLOBULINAEMIA (WM) BY TESTING FOR MYD88 L265P MUTATIONS	Wolfgang Willenbacher	Received

210-P	ABT-199 IS HIGHLY EFFECTIVE AGAINST MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA HARBORING T(11;14) TRANSLOCATION	Cyrille Touzeau	Received

214-P	MULTIDIMENSIONAL FLOW CYTOMETRY IMMUNOPHENOTYPIC QUANTIFICATION AND CHARACTERIZATION OF IN VIVO MESENCHYMAL STEM CELLS IN MGUS AND MULTIPLE MYELOMA	Rui Leite	Received

216-P	AN EGFP IMAGING BASED IN VIVO MODEL FOR STUDYING THE BIOLOGY AND TREATMENT OF MULTIPLE MYELOMA	lisha ai	Received

217-P	IDENTIFICATION OF POTENTIAL DRUG TARGETS WITHIN THE UBIQUITIN PROTEASOME SYSTEM IN MULTIPLE MYELOMA	Lisa Crawford	Received

218-P	MULTIPARAMETER FLOW CYTOMETRY DETECTION OF CLONAL PLASMA CELLS IN THE BONE MARROW OF PATIENTS WITH SOLITARY PLASMACYTOMA DETERMINES THE RISK OF PROGRESSION TO ACTIVE MYELOMA	Bruno Paiva	Received

219-P	CAN IMMUNOPHENOTYPIC CR BE ALSO ACHIEVED IN RELAPSED MULTIPLE MYELOMA PATIENTS?	Bruno Paiva	Received

220-P	MYELOMA PLASMA CELLS ALTER THE BONE MICROENVIRONMENT BY STIMULATING AN INCREASE IN MESENCHYMAL STEM CELL NUMBERS	Jacqueline Noll	Received

221-P	EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL	Francesca Gay	Received

223-P	BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE VERSUS THALIDOMIDE-DEXAMETHASONE PLUS AUTOTRANSPLANTATION FOR MULTIPLE MYELOMA: UPDATED FOLLOW-UP AND OUTCOMES AFTER RELAPSE IN THE PHASE 3 GIMEMA-MMY-3006 TRIAL	paola tacchetti	Received

226-P	MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)	Paul Richardson	Received

227-P	TANDEM AUTOLOGOUS/ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS IN FIRST LINE HIGH RISK MULTIPLE MYELOMA PATIENTS: EVOLVING STRATEGIES WITH THE IMMUNOMODULATING DRUGS	Mauricette Michallet	Received

231-P	BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY MM PROGRESSIVE AFTER 1ST LINE THERAPY (IFM 2009-01 TRIAL): PREDICTIVE FACTORS OF DEFAVOURABLE OUTCOME	Philippe Rodon	Received

235-P	A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA	Hiroyuki Takamatsu	Received

241-P	IMPACT OF HISTORY OF AUTOIMMUNE DISEASE ON SURVIVAL IN MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE	Ebba Lindqvist	Received

242-P	LOW RATE OF SECONDARY PRIMARY MALIGNANCIES (SPMS) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH LENALIDOMIDE: FIRST RESULTS FROM THE MRC MM XI TRIAL	Annamaria Brioli	Received

243-P	THERAPY FOLLOWING RELAPSE ON MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) FOLLOWED BY LEN MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EFFICACY AND SAFETY OF SECOND LINE LEN IN MM-015	Meletios Dimopoulos	Received

244-P	ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	Katja Weisel	Received

245-P	SALVAGE TREATMENT WITH POMALIDOMIDE-CYCLOPHOSPHAMIDE-PREDNISONE PRODUCES SIMILAR OUTCOMES AS COMPARED TO PRIOR THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Alessandra Larocca	Received

248-P	A MOUSE MODEL FOR HUMAN MYELOFIBROSIS	IOANNA TRIVIAI	Received

249-P	DEREGULATED MIRNAS IN JAK2V617F-NEGATIVE ESSENTIAL THROMBOCYTHEMIA PATIENTS TARGET SOCS FAMILY MEMBERS	Beatriz Bellosillo	Received

250-P	A DIFFERENTIAL CENTROSOME LOCALIZZATION OF WILD TYPE (WT) AND JAK2V617F PROTEIN IN HUMAN LEUKEMIA CELL LINES	Biagio De Angelis	Received

251-P	EVALUATION OF THROMBIN GENERATION POTENTIAL IN POLYCYTHEMIA VERA PATIENTS ENROLLED IN THE CYTO-PV ITALIAN CLINICAL TRIAL	Marina Marchetti	Received

253-P	A TRANSLOCATION T(3 ;13)(Q13 ;Q12) FUSES FLT3 TO A NOVEL PARTNER GENE, GOLGB1, IN A MYELOID/LYMPHOID NEOPLASM WITH EOSINOPHILIA.	Estelle TROADEC	Received

255-P	INCREASED PREVALENCE OF AUTOIMMUNE PHENOMENA IN MYELOFIBROSIS: RELATIONSHIP WITH CLINICAL AND MORPHOLOGICAL CHARACTERISTICS, AND WITH IMMUNOREGULATORY CYTOKINE PATTERNS	Francesca Guidotti	Received

257-P	ALL-TRANS RETINOIC ACID POTENTIATES THE INHIBITORY EFFECTS OF INTERFERON ALPHA (IFN) ON CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN) PROGENITORS IN VITRO.	Novella Pugliese	Received

258-P	SETBP1 OVEREXPRESSION IN CLASSICAL BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS	Francesco Albano	Received

259-P	CUSTOM AMPLICON CAPTURE AND BENCH-TOP HIGH THROUGHPUT SEQUENCING TO SCREEN FOR MUTATIONS ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASMS	Gareth Gerrard	Received

260-P	QUANTITATIVE RT-PCR FOR PDGFR IS USEFUL FOR DIAGNOSIS AND MOLECULAR MONITORING OF PATIENTS WITH PDGFR REARRANGEMENTS TREATED WITH TYROSINE-KINASE INHIBITORS	Eric Lippert	Received

261-P	CHARACTERIZATION OF PLATELET HYPERCOAGULABILITY IN HIGH-HEMATOCRIT POLYCYTHEMIA VERA PATIENTS	Marina Marchetti	Received

262-P	CHARACTERIZATION OF MUTATIONS IN ASXL1, SRSF2, CBL AND JAK2 GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA	Laura Palomo	Received

263-P	ADDITIONAL MUTATIONS TARGETING GENES UNRELATED TO RAS PATHWAY ARE FOUND IN SPORADIC JMML BUT NOT IN SYNDROMIC JMML	Aurélie Caye	Received

264-P	DETECTION OF LEUKEMIA-ASSOCIATED MUTATIONS IN HEMATOLOGICALLY NORMAL ELDERLY INDIVIDUALS	Joannah Score	Received

265-P	THE IDENTIFICATION OF A PSTAT5 GENE SIGNATURE AND ITS MODULATION IN RUXOLITINIB PHARMACODYNAMIC RESPONSE IN HEMATOLOGIC MALIGNANCY	Jessica Litvan	Received

266-P	DO MYELOPROLIFERATIVE NEOPLASMS (MPNS) HAVE STAGES? ANALYSIS OF RELATIONSHIP OF DISEASE DURATION, PROGNOSTIC SCORES, AND SYMPTOMATIC BURDEN OF 1467 MPN PATIENTS	Holly Geyer	Received

268-P	MUTATIONS IN THE RNA SPLICING MACHINERY GENES IN MYELOFIBROTIC TRANSFORMATION OF ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA	Beatriz Bellosillo	Received

269-P	MULTIVARIATE ANALYSIS OF THE ASSOCIATION OF CYTOKINE LEVELS AND REDUCTIONS IN SPLEEN SIZE IN COMFORT-II, A PHASE 3 STUDY COMPARING RUXOLITINIB TO BEST AVAILABLE THERAPY (BAT)	Jessica Litvan	Received

270-P	SPLICEOSOME COMPONENT MUTATIONS AND CYTOGENETIC CORRELATES IN WORLD HEALTH ORGANIZATION (WHO)-DEFINED CHRONIC MYELOMONOCYTIC LEUKEMIA	Sameer Parikh	Received

271-P	ACQUIRED COPY-NEUTRAL LOSS OF HETEROZIGOSITY OF CHROMOSOME 1P AS A MOLECULAR EVENT ASSOCIATED WITH MARROW FIBROSIS IN MPL MUTATED MYELOPROLIFERATIVE NEOPLASMS	elisa rumi	Received

273-P	MYELOPROLIFERATIVE NEOPLASM QUALITY OF LIFE (MPN-QOL) STUDY GROUP: DUAL SERIAL ASSESSMENT STUDIES FOR IMPACT OF STANDARD THERAPEUTIC APPROACHES IN MPN POPULATIONS (MEASURE AND SYMPTOMS TRIALS)	Holly Geyer	Received

274-P	LONG-TERM EFFICACY AND SAFETY OF CLADRIBINE (2-CDA) IN ADULT PATIENTS WITH MAST CELL DISEASE : A FRENCH MULTICENTER STUDY OF 68 PATIENTS	stephane BARETE SB	Received

275-P	CIRCULATING YKL-40 IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) TREATED WITH THE NOVEL HISTONE DEACETYLASE INHIBITOR VORINOSTAT	Christen Andersen	Received

276-P	IMPACT OF HEMATOCRIT ON SYMPTOM BURDEN AMONG POLYCYTHEMIA VERA PATIENTS	Robyn Emanuel	Received

277-P	WHITE BLOOD CELLS COUNT INFLUENCE THE PROGNOSIS OF POLYCYTHEMIA VERA PATIENTS: A SUB-ANALYSIS OF THE CYTO-PV STUDY.	RICCARDO CAVAZZINA	Received

278-P	Safety Overview of Phase 1-2 Studies of Pacritinib, a Non-Myelosuppressive JAK2/FLT3 inhibitor, in Patients with Hematological Malignancies	Kristin MacIntosh	Received

279-P	A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF)	Christen Andersen	Received

280-P	CLINICAL FEATURES OF ESSENTIAL THROMBOCYTHEMIA WITH SPLEEN ENLARGEMENT: THE EXPERIENCE OF LAZIAL GROUP FOR THE STUDY OF SMPC, PH-.	Alessandro Andriani	Received

284-P	DETECTION OF PERIPHERAL BLOOD MONOCLONAL T LYMPHOCYTOSIS AND RISK OF T LYMPHOPROLIFERATIVE DISEASE DEVELOPMENT	Giuseppe Tagariello	Received

286-P	VITAMIN D3 AND LENALIDOMIDE SYNERGIZE TO INDUCE APOPTOSIS IN MANTLE CELL LYMPHOMA VIA DEMETHYLATION OF BIK	Carole Brosseau	Received

288-P	THE HOST GENETIC BACKGROUND MODULATES TREATMENT ACTIVITY AND TOXICITY IN FOLLICULAR LYMPHOMA: FIL-FOLL05 TRIAL	Giuseppe Palumbo	Received

292-P	MYD88 L265P MUTATION IN WALDENSTROM MACROGLOBULINEMIA : INCIDENCE AND FUNCTIONAL STUDY	Stephanie Poulain	Received

294-P	B-CELL REPERTOIRE ANALYSIS OF INDOLENT MCL WITH SPLENIC PRESENTATION : A DISTINCT ONTOGENY FROM CLASSICAL MCL?	clémentine sarkozy	Received

296-P	INFLUENCE OF THE B-CELL RECEPTOR (BCR) SIGNALING PATHWAYS ON CD20 LEVELS IN TUMOR CELLS AND ANTITUMOR ACTIVITY OF ANTI-CD20 MONOCLONAL ANTIBODIES	Magdalena Winiarska	Received

297-P	GENETIC VARIATION IN INTERFERON REGULATORY FACTOR 4 AND INTERLEUKIN 10 GENES, AND THE RISK FOR DIFFUSE LARGE B-CELL LYMPHOMA	In-Suk Kim	Received

298-P	PROGNOSTIC IMPACT OF EZH2 EXPRESSION, H3K27 TRIMETHYLATION AND DNA METHYLATION IN DIFFUSE LARGE B CELL LYMPHOMA	Shih-Chiang Lin	Received

299-P	BMI1 EXERTS ITS ONCOGENIC EFFECTS VIA ENHANCEMENT OF ANTI-APOPTOTIC POTENTIAL IN MANTLE CELL LYMPHOMA	kazuaki teshima	Received

300-P	THE ROLE OF CXCCHEMOKINE IL-8, IL-6 AND CXCR2 RECEPTOR IN LYMPHOPLASMACYTIC LYMPHOMA: CORRELATIONS WITH MICROVASCULAR CHARACTERISTICS AND CLINICAL FEATURES	Georgia Levidou	Received

301-P	HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA	Rita Coutinho	Received

302-P	Upfront allogenic stem cell transplantation in patients with advanced T-cell lymphomas : an intention-to-treat analysis from a single institution	Marion Loirat	Received

304-P	R-CHOP21 VS R-CHOP14 IN 1024 DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS FROM A MULTICENTRE RETROSPECTIVE STUDY OF FONDAZIONE ITALIANA LINFOMI (FIL)	Luigi Rigacci	Received

305-P	SINGLE-AGENT LENALIDOMIDE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMBINED ANALYSIS FROM THE MCL-001, NHL-002, AND NHL-003 STUDIES	Marybeth McKenzie	Received

307-P	INFERIOR OUTCOME OF ELDERLY DLBCL PTS WITH 25-OH VITAMIN D DEFICIENCY TREATED WITH CHOP PLUS RITUXIMAB: RESULTS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP DSHNHL	Jrg Thomas Bittenbring	Received

310-P	PIXANTRONE MONOTHERAPY IN HISTOLOGICALLY CONFIRMED, RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: POST HOC ANALYSIS FROM A PHASE III TRIAL	Arthur Smyth Medina	Received

311-P	SOX11 CAN BE USED AS A LONGITUDINAL MINIMAL RESIDUAL DISEASE MARKER FOR MANTLE CELL LYMPHOMA	Anita Simonsen	Received

312-P	CONTRIBUTION OF CEREBROSPINAL FLUID SCD19 LEVELS TO THE DETECTION OF CNS LYMPHOMA: IMPACT ON DISEASE OUTCOME	Lourdes Martin Martin	Received

313-P	RITUXIMAB-PECC FOLLOWED BY 90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION IN RELAPSED OR REFRACTORY DLBCL PATIENTS WHO ARE NOT ELIGIBLE FOR OR AFTER ASCT: PRELIMINARY RESULTS FROM A PHASE II HOVON STUDY	Pieternella Lugtenburg	Received

316-P	EFFICACY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN ELDERLY PATIENTS WITH AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: A MULTICENTRIC STUDY.	Federica Loscocco	Received

317-P	THE ROLE OF PET/CT AFTER RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): RESPONSE ASSESSMENT, PROGNOSTIC SIGNIFICANCE AND IMPLICATIONS FOR SUBSEQUENT RADIOTHERAPY (RT)	Theodoros Vassilakopoulos	Received

319-P	THE LYMPHOCYTES TO MONOCYTES RATIO IDENTIFIES A PATIENT SUBGROUP AMONG HIGH RISK DLBCL THAT MAY BENEFIT FROM UPFRONT INTENSIVE TREATMENT WITH AUTOGRAFT	Anna Maria Barbui	Received

321-P	NON-INTERVENTIONAL STUDY BE-1ST: FIRST LINE THERAPY WITH BENDAMUSTINE IN ADVANCED INDOLENT NON-HODGKIN LYMPHOMA (NHL) IN TREATMENT ROUTINE	Tessa Schliephacke	Received

322-P	THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA	Maria Chiara Tisi	Received

324-P	LYMPHOMAS WITH MYC-TRANSLOCATION OTHER THAN BURKITTS: BAD PROGNOSIS DESPITE SPECIFIC IMMUNOCHEMOTHERAPY FOR BURKITTS LYMPHOMA	José Tomás Navarro	Received

326-P	THE POTENTIAL OF CD127 AS A PROGNOSTIC AND RESIDUAL DISEASE MARKER IN CHRONIC ADULT T CELL LEUKEMIA/LYMPHOMA.	Huseini Kagdi	Received

327-P	EVALUATION OF THE PROGNOSTIC SIGNIFICANCE OF THE BODY MASS INDEX (BMI) IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) RECEIVING RITUXIMAB-CHOP (R-CHOP) OR SIMILAR IMMUNOCHEMOTHERAPY	Theodoros Vassilakopoulos	Received

328-P	AIDS-RELATED LYMPHOMAS (ARL), OUTCOME AND PROGNOSTIC FACTORS	TERESA GARRIDO	Received

330-P	THE USE OF SYSTEMIC THERAPY DOES NOT IMPROVE THE RESULTS OF LOCOREGIONAL TREATMENT IN LIMITED STAGE (I-II) FOLLICULAR LYMPHOMA: STUDY OF 112 PATIENTS.	Juan-Manuel Sancho	Received

332-P	CLINICAL AND MOLECULAR SIGNIFICANCE OF TUMOR NECROSIS IN NEWLY DIAGNOSED PATIENTS WITH HODGKINS LYMHOMA AND DIFFUSE LARGE B CELL LYMPHOMA	Ihab Abd el rahman	Received

335-P	CLINICAL RELEVANCE OF INTERNATIONAL PROGNOSTIC INDEX AS A PREDICTOR FOR VENOUS THROMBOEMBOLISM IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY	Sung Hee Lim	Received

338-P	LOWER INCIDENCE OF EBV-POSITIVITY IN ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA: POSSIBLE NEW SUBGROUP OF ELDERLY B-CELL LYMPHOMA	Tatsuki Tomikawa	Received

341-P	UTILITY OF F-18 FDG PET/CT FOR THE DIAGNOSIS AND THERAPEUTIC MANAGEMENT FOR EXTRANODAL NATURAL KILLER (NK)/T CELL LYMPHOMA, NASAL TYPE	Bing Xu	Received

344-P	LONG TERM SURVEY OF 180 PATIENTS TRANSPLANTED AFTER RIC REGIMEN USING THREE DOSES OF ATG: A BELGIAN HEMATOLOGY SOCIETY (BHS) NATIONAL PROSPECTIVE TRIAL	Dominique Bron	Received

345-P	SPECTRUM OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Qifa Liu	Received

346-P	ENTERAL VERSUS PARENTERAL NUTRITIONAL SUPPORT POST ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION RESULTS OF A RANDOMIZED CONTROLLED TRIAL	Sarah Andersen	Received

347-P	COMBINED CMV REPLICATION AND CHRONIC GVHD GENERATE A SIGNIFICANT SYNERGY OF ANTI-LEUKEMIC EFFECT AFTER ALLOGENEIC HSCT IN ACUTE MYELOID LEUKEMIA	Ji Eun Jang	Received

348-P	HUMAN HERPESVIRUS-6 REACTIVATION AND HHV-6 ENCEPHALITIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER, PROSPECTIVE STUDY.	Masao Ogata	Received

349-P	CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN AML PATIENTS WITH CNS DISEASE UNDERGOING ALLOGENIC STEM CELL TRANSPLANTATION- RISK FACTORS AND PROGNOSIS	Mrinal Patnaik	Received

350-P	COMPARISON OF MESENCHYMAL STEM CELLS AND MESENCHYMAL STEM CELLS COMBINED WITH CORD BLOOD FOR TREATMENT OF ENGRAFT FAILURE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE PI	Qifa Liu	Received

351-P	ABCG2 OVEREXPRESSION NEGATIVELY AFFECT OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT IN ACUTE MYELOID LEUKEMIA PATIENTS	Mario Tiribelli	Received

353-P	A LEBANESE-ITALIAN COLLABORATIVE INITIATIVE ON BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ?-THALASSEMIA MAJOR	Hussein Abbas	Received

356-P	CIDOFOVIR AS SECOND LINE THERAPY IN CMV REACTIVATION: CLINICAL AND BIOLOGICAL CORRELATES.	Francesca Farina	Received

357-P	IS IMATINIB MAINTENANCE REQUIRED FOR PATIENTS WITH RELAPSE CHRONIC MYELOID LEUKEMIA POST-TRANSPLANTATION OBTAINING CMR? A PILOT RETROSPECTIVE INVESTIGATION	Qifa Liu	Received

359-P	UNRELATED CORD BLOOD TRANSPLANTATION FOR CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA	Changcheng Zheng	Received

360-P	LENOGRASTIM FROM DAY 7 AND PEGFILGRASTIM ARE EQUALLY EFFECTIVE IN REDUCING TIME TO NEUTROPHIL ENGRAFTMENT, ANTIBIOTIC USE AND INPATIENT STAY IN PATIENTS WITH MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANT	Benjamin Bailiff	Received

361-P	TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE.	CARMEN ALBO	Received

364-P	DONOR AND RECIPIENT STR ANALYSIS BEFORE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: POSSIBLE CORRELATION WITH POST-TRANSPLANT OUTCOME	Sabrina Giammarco	Received

365-P	COMPARISON BETWEEN LONG-TERM AND SHORT-TERM ADMINISTRATION OF ITRACONAZOLE FOR PRIMARY ANTIFUNGAL PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER, RANDOMIZED TRIAL	Qifa Liu	Received

366-P	BENDAMUSTINE, ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCE LONG-LASTING COMPLETE REMISSIONS IN A HIGH PROPORTION OF RESISTANT/RELAPSED LYMPHOMA PATIENTS: 32 MONTHS FOLLOW-UP UPDATE.	Alessandro Isidori	Received

367-P	A CONDITIONING PLATFORM WITH FLUDARABINE, BUSULFAN AND ATG CONDUCTS TO IDENTICAL PROMISING RESULTS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM BOTH MATCHED AND MISMATCHED UNRELATED DONOR	devillier raynier	Received

368-P	MOLECULAR MONITORING AND STEPWISE PREEMPTIVE THERAPY FOR EPSTEIN-BARR VIRUS VIREMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Qifa Liu	Received

371-P	REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULTS USING FLUDARABINE, BCNU, MELPHALAN, AND ANTITHYMOCYTE GLOBULIN (FBM-A): OUTCOMES DEPEND ON DISEASE RISK INDEX	Jose Leis	Received

373-P	PREDICTION OF MOBILIZATION FAILURE FOR PRE-EMPTIVE PLERIXAFOR ADMINISTRATION: THE PAMPLONA PROTOCOL	AMAYA ZABALZA	Received

374-P	DOES ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOME THE ADVERSE RISK OF FLT3 POSITIVIVITY IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKAEMIA?	Sorcha Ni Loingsigh	Received

376-P	RITUXIMAB-BASED TREATMENTS FOLLOWED BY ADOPTIVE CELLULAR THERAPIES FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Qifa Liu	Received

378-P	A GENETIC VARIANT IN THE CD53 INTRON FUNCTIONALLY PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED BONE MARROW TRANSPLANTATION	Akiyoshi Takami	Received

379-P	RELATIONSHIP BETWEEN INFUSION FEVER FOLLOWING PERIPHERAL BLOOD STEM CELL AND PERI-ENGRAFTMENT SYNDROME IN PEADIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION	YAO CHEN	Received

381-P	STENOTROPHOMONAS MALTOPHILIA INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION -RISK FACTORS AND THERAPEUTIC STRATEGIES-	Shiratori Souichi	Received

387-P	ERYTHROPOIETIN IMPROVES BRAIN DEVELOPMENT IN SHORT-TERM HY0POXIA IN RAT EMBRYO CULTURES	Yasemin Altuner Torun	Received

388-P	DISULFIRAM/COPPER COMPLEX COULD ELIMINATE RAJI CELLS IN VITRO AND VIVO THROUGH ACTIVATION OF OXIDATIVE STRESS AND INHIBITION OF NRF2 AND NF-?B	Bing Xu	Received

391-P	THE SAFETY PROFILE OF DEFERASIROX REMAINS CONSISTENT AS NON-TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS APPROACH THE TARGET LIVER IRON CONCENTRATION OF 3 MG FE/G DW FOR INTERRUPTING CHELATION	Germanicus Hansa-Wilkinson	Received

392-P	PROGNOSTIC CMR PARAMETERS FOR HEART FAILURE AND ARRHYTHMIAS IN A LARGE COHORT OF WELL TREATED THALASSEMIA MAJOR PATIENTS	Antonella Meloni	Received

393-P	IMPACT OF MONITORING WITH LIVER MRI-R2 ON LIVER IRON BURDEN AND DEVELOPMENT OF ENDOCRINOPATHIES: A RETROSPECTIVE AUDIT	Stephanie Ko	Received

394-P	MYOCARDIAL FIBROSIS BY CMR LGE IN A LARGE COHRT OF PEDIATRIC THALASSEMIA MAJOR PATIENTS	Antonella Meloni	Received

395-P	CMR SURVEY IN A LARGE COHORT OF TI PATIENTS CATEGORIZED IN DIFFERENT TRANSFUSIONAL REGIMENS	Antonella Meloni	Received

396-P	EVALUATION OF GLYCAEMIC ABNORMALITIES IN ?ETA THALASSEMIA MAJOR USING CONTINUOUS GLUCOSE MONITORING SYSTEM AND ORAL GLUCOSE TOLERANCE TEST	Mohamed AbdelDaem Mohamed Yassin	Received

398-P	EFFECTS OF THE ANTI RANK LIGAND DENUSOMAB ON BETA THALASSEMIA MAJOR-INDUCED OSTEOPOROSIS	Mohamed AbdelDaem Mohamed Yassin	Received

399-P	REFERENCE RANGES FOR BIVENTRICULAR VOLUMES AND EJECTION FRACTION AND FOR LEFT VENTRICULAR MASS IN ADULT THALASSEMIA INTERMEDIA PATIENTS WITHOUT MYOCARDIAL IRON OVERLOAD	Antonella Meloni	Received

400-P	CLINICAL EVOLUTION IN FOUR CARRIERS OF BETA GLOBIN LOCUS DELETIONS	Felix De la Fuente	Received

401-P	PITUITARY MRI IN CORRELATION WITH IRON OVERLOAD AND HYPOGONADISM IN YOUNG THALASSEMIA MAJOR PATIENTS	Amira Adly	Received

402-P	HBH CONSTANT SPRING DISEASE (HBHCS) HAS LOWER SERUM FERRITIN RELATIVE TO LIVER IRON CONCENTRATION (LIC) COMPARED TO DELETIONAL HBH DISEASE: IMPORTANCE OF LIC MEASUREMENT IN HBHCS	Ai Leen Ang	Received

403-P	AN AUTOMATIC METHOD FOR MYOCARDIAL T2 CURVE FITTING IN THALASSEMIA PATIENTS WITH SEVERE IRON OVERLOAD	Antonella Meloni	Received

404-P	MOVEMENT ABNORMALITIES IN THE LEFT VENTRICLE OF THALASSEMIA MAJOR PATIENTS	Antonella Meloni	Received

406-P	Mortality sickle cell diseaserisk factors in a Dutch cohort	Marein Schimmel	Received

407-P	PRASUGREL IN CHILDREN WITH SICKLE CELL DISEASE: PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS FROM AN OPEN-LABEL, ADAPTIVE-DESIGN, DOSE-RANGING STUDY	Julie Sherman	Received

410-P	NEWBORN SCREENING FOR SICKLE CELL DISEASE IN BRUSSELS, A PROGRAM WITH AN ONGOING CLINICAL OUTCOME IMPROVEMENT	Phu-Quoc L	Received

411-P	ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE INTRONE4 VNTR POLYMORPHISM IN SICKLE CELL DISEASE AND TRANSFUSION-DEPENDENT ?-THALASSEMIA MAJOR: RELATION TO CARDIO-VASCULAR COMPLICATIONS	Azza Tantawy	Received

412-P	ANTENATAL SCREENING PROGRAMME FOR HAEMOGLOBINOPATHY IN A LOW PREVALENCE AREA: IS IT EFFECTIVE?	ANANDIKA LIYANAGE	Received

413-P	FG4592, A NOVEL INHIBITOR OF THE PROLYL HYDROXYLASE OF HYPOXIA-INDUCIBLE FACTOR (HIF-PH) ELICITED LINEAR-EXPONENTIAL DOSE-RESPONSE PROFILE ON PLASMA ERYTHROPOIETIN (EPO) LEVELS	Xia Chen	Received

415-P	DEVELOPMENT OF A LABORATORY PATHWAY TO ASSIST THE DIAGNOSIS OF HEREDITARY HAEMOCHROMATOSIS IN PRIMARY CARE	Catherine Ogilvie	Received

418-P	INTRAVENOUS IRON THERAPY FOR TREATMENT OF ANEMIA DURING PREGNANCY IS ASSOCIATED WITH IMPROVED MATERNAL QUALITY OF LIFE, LESS POSTNATAL DEPRESSION AND LONGER BREASTFEEDING	Alhossain Khalafallah	Received

420-P	STUDY OF IRON STATUS AS A CONTRIBUTING FACTOR TO ANEMIA IN PEDIATRIC CANCER PATIENTS	Azza Tantawy	Received

424-P	FOUR MEASURES TO REDUCE THE RATE OF HEALTH CARE-ASSOCIATED BLOODSTREAM INFECTIONS RELATED TO THE USE OF NEEDLESS MECHANICAL VALVE CONNECTORS IN LONG-TERM CENTRAL VENOUS CATHETERS	Nélson Domingues	Received

427-P	A RETROSPECTIVE STUDY OF THE RELATIONSHIP BETWEEN VITAMIN D SUPPLEMENTATION AND THE RISK OF FEBRILE NEUTROPENIA(FN) IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES IN EAST KENT HOSPITALS(EKUFHT)	Salah-Eldin Alhassan	Received

428-P	INFECTIONS CAUSED BY CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES	Maria Stamouli	Received

431-P	ABNORMAL SPLEEN FUNCTION ASSESSED BY THE STUDY OF PITS AND SUBMEMBRANOUS VACUOLES IN ERYTHROCYTES IN PATIENTS WITH SPLENOMEGALY OF DIFFERENT ETIOLOGY	EVARIST FELIU	Received

432-P	NEUTROPENIC ENTEROCOLITIS AND VANCOMYCIN RESISTANT ENTEROCOCCUS AS PREDISPOSING FACTOR	Elif Gulsum Umit	Received

433-P	ANAEROBIC BLOODSTREAM INFECTIONS AMONG HAEMATOLOGICAL CANCER PATIENTS: EPIDEMIOLOGY AND OUTCOME. RESULTS OF AN 8-YEAR SURVEILLANCE PROGRAM AT A SINGLE INSTITUTION	Chiara Cattaneo	Received

434-P	COMPARISON OF THE BD GENEOHMVANR ASSAY TO CULTURE FOR IDENTIFICATION OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN RECTAL AND STOOL SPECIMENS IN PEDIATRIC MALIGNANCY PATIENTS	yaman yntem	Received

435-P	REASONS FOR TREATMENT SEEKING DELAY IN NEUTROPENIC SEPSIS	Marc Talbot	Received

436-P	CEFEPIME-INDUCED ENCEPHALOPATHY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: CLINICAL FEATURES AND RISK FACTORS	Tomotaka Ugai	Received

438-P	USEFULNESS OF GALACTOMANNAN ASSAY IN BRONCHOALVEOLAR LAVAGE SAMPLES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND RISK OF INVASIVE PULMONARY ASPERGILLOSIS.	Rafael Del Orbe Barreto	Received

439-P	RISK FACTORS RELATED TO MORTALITY IN HEMATOLOGICAL PATIENTS ADMITTED TO INTENSIVE CARE UNIT (ICU)	Sandra Iraheta	Received

442-P	DIAGNOSTIC EFFICACY OF GALACTOMANNAN ASSAY AND COMPUTERIZED CHEST TOMOGRAPHY IN INVASIVE ASPERGILLOSIS OF FEBRILE NEUTROPENIC CHILDREN	Gonul Aydogan	Received

443-P	VESICLES OBSERVED IN LEUCOREDUCED AND NON LEUCOREDUCED CONCENTRATED RED BLOOD CELLS BY MEANS OF ADVANCED MICROSCOPES: POSSIBLE RELATION TO THE STORAGE LESION	Dimosthenis Stamopoulos	Received

445-P	Alloantibody formation is increased in Sickle Cell Disease patients compared to the general population	Joep Sins	Received

446-P	THE ROLE OF BLOOD TRANSFUSION IN BETA-THALASSEMIA: AN EX VIVO STUDY OF HEMOSTATIC PARAMETERS	Alice Trinchero	Received

448-P	TRANSCRIPTIONAL PROFILING OF HUMAN ERYTHROID PROGENITORS FROM G-CSF MOBILIZED AND NONMOBILIZED PERIPHERAL BLOOD	Vladan Cokic	Received

450-P	MATERNAL AND FETAL OUTCOMES IN PREGNANT PATIENTS WITH SICKLE CELL DISEASE WHO APPLIED PROPHYLACTIC RED BLOOD CELL EXCHANGE PROCEDURE	Ilknur Kozanoglu	Received

452-P	ANCESTIM VERSUS PLERIXAFOR FOR THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS	Adrian Tempescul	Received

453-P	BONE MARROW ASPIRATE MORPHOLOGIC, IMMUNOPHENOTYPIC AND CYTOGENETIC EVALUATION IN RELATED DONORS PRIOR TO HEMATOPOIETIC STEM CELL DONATION	Raffaella Milani	Received

454-P	THE USE OF PREOPERATIVE ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WHO UNDERWENT KNEE OR HIP ARTHROPLASTY	Ghazi Alotaibi	Received

456-P	FAILURE ON MAINTAINING HAEMOGLOBIN LEVEL AFTER TRANSFUSION IN TRANSFUSION DEPENDENT THALASSEMIA PATIENTS RELATED TO ERYTHROCYTE ALLOANTIBODY AND AUTOANTIBODY PRODUCTION: PROPORTION AND REL	Andree Kurniawan	Received

457-P	EFFECT OF USING LEUKOSTOP FILTER DURING BLOOD TRANSFUSION ON PULMONARY FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR	Iman Ragab	Received

458-P	PLATELET TRANSFUSIONS IN HAEMATOLOGY PATIENTS	bachra choufi	Received

459-P	THE EFFECTIVENESS OF PLATELETS TRANSFUSIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML) DURING INDUCTION CHEMOTHERAPY (IC).	Bulgan Davaasambuu	Received

460-P	MEASUREMENT OF IRON CONCENTRATION IN HAIR AS AN INDICATOR OF BODY IRON LOAD	Yasemin Altuner Torun	Received

461-P	REVIEW AND DESIGN OF A NEW BLOOD BOOKING PROTOCOL FOR EACH SURGERY AND A RESTROSPECTIVE STUDY OF THE DIRECT EXPENSE DECREASE WITH THE NEW PROTOCOL	Angel Pereda Vicandi	Received

462-P	A CANADIAN TALE OF TWO BLOOD GROUPS	Conal McConville	Received

466-P	RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN COMBINATION WITH LOW-DOSE RITUXIMAB (LD RTX) IN SEVERE OR REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER PROSPECTIVE CLINICAL TRIAL	MING HOU	Received

470-P	RITUXIMAB VERSUS SPLENECTOMY IN PERSISTENT OR CHRONIC ADULT PRIMARY IMMUNE THROMBOCYTOPENIA: AN ADJUSTED COMPARISON OF MORTALITY AND MORBIDITY	Guillaume Moulis	Received

471-P	EVALUATION OF THE IMMATURE PLATELET FRACTION IN THE DIAGNOSIS AND PROGNOSIS OF CHILDHOOD IDIOPATHIC THROMBOCYTOPENIC PURPURA	Amira Adly	Received

472-P	THALIDOMIDE CORRECTS IMPAIRED MESENCHYMAL STEM CELL FUNCTION IN INDUCING TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	JUN PENG	Received

473-P	DISEASE PROGRESSION, TREATMENT PATTERNS, AND CO-MORBID BURDEN AMONG ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UPDATED RESULTS FROM THE UNITED KINGDOM ITP REGISTRY	Dimitri Bennett	Received

474-P	THROMBOEMBOLIC EVENTS IN PATIENTS WITH ADULT CHRONIC IMMUNE THROMBOCTOPENIA (ITP) TREATED WITH ELTROMBOPAG	shojiro Takagi	Received

475-P	MANAGEMENT OF ADULT CHRONIC IMMUNE THROMBOCYTOPENIA IN JAPAN: PATIENT AND HEMATOLOGIST PERSPECTIVES	Norio Komatsu	Received

476-P	D-DIMER LEVELS IN ACUTE IDIOPATHIC AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA	Andrew Grosset	Received

477-P	THROMBOCYTOPENIA IN PREGNANCY: OUR EXPERIENCE AT THE NATIONAL MATERNITY HOSPITAL	MATIAS DIAZ	Received

478-P	MONITORING ANTIPLATELET THERAPY : ACTIVITY OF ADENOSINE DIPHOSPHATE RECEPTOR INHIBITORS IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION	Marian Fedor	Received

479-P	ANALYSIS OF RETICULATED PLATELETS IN THE ROUTINE CLINICAL PRACTICE USING THE CELL-DYN SAPPHIRE INSTRUMENT	Hans Wadenvik	Received

481-P	THE ROLE OF OXIDATIVE STRESS IN CHILDREN WITH ACUTE AND CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA	Erol Erduran	Received

482-P	PILOT OBSERVATIONAL STUDY OF ROTATIONAL THROMBOELASTOMETRY (ROTEM) TO PREDICT BLEEDING RISK IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (ATHENA STUDY)	Lise Estcourt	Received

483-P	AUTOCRINE AMPLIFICATION OF INTEGRIN aIIBb3 ACTIVATION AND PLATELET ADHESIVE RESPONSES BY DEOXYRIBOSE-1-PHOSPHATE	Dina Vara	Received

484-P	INCREASED CIRCULATING MICROPARTICLES COEXPRESSING ENDOTHELIAL AND PLATELET MARKERS IN ISCHEMIC CEREBRAL STROKE	Ghada Ezzat	Received

485-P	LOW MOLECULAR WEIGHT HEPARIN (LMWH) FOR PRIMARY THROMBOPROPHYLAXIS OF AMBULATORY PATIENTS WITH SOLID CANCER SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Anat Gafter-Gvili	Received

486-P	PLATELET COUNTS DECREASE WITH INCREASING LUPUS-LIKE ANTICOAGULANT RATIOS, IRRESPECTIVE OF ANTIPHOSPHOLIPID SYNDROME CRITERIA	Marta Pereira	Received

487-P	REDOX-DEPENDENT ANGIOGENESIS BY NUCLEOSIDE DERIVATIVES OF DEOXYRIBOSE-1-PHOSPHATE	Dina Vara	Received

488-P	THE JAK2 V617F MUTATION IN PATIENTS WITH CEREBRAL VENOUS THROMBOSIS IS ASSOCIATED WITH AN INCREASED RISK OF RECURRENCE	Valerio De Stefano	Received

490-P	ADVANTAGES AND DISADVANTAGES OF INCORPORATING C-REACTIVE PROTEIN LEVELS, AGE AND D-DIMER LEVELS IN DIAGNOSING PULMONARY EMBOLISM	Meindert Crop	Received

491-P	EVALUATING ACQUIRED DISORDERS OF PROTEIN C SYSTEM IN PATIENTS ON VITAMIN K ANTAGONISTS TREATMENT BY THE CALIBRATED AUTOMATED THROMBOGRAM	Veronika Shmeleva	Received

493-P	THE ROLE OF ANTICOAGULANT THERAPIES ON COAGULOPATHY (DISSEMINATED INTRAVASCULAR COAGULATION) IN PATIENTS WITH HEMOLYTICUREMIC SYNDROME AFTER INFECTION WITH ENTEROHEMORRHAGIC ESCHERICHIA COLI O111.	Jun Murakami	Received

494-P	UNEXPECTED FATAL PULMONARY EMBOLISM FOUND AT FORENSIC AUTOPSIES	Mariana Villegas Scivetti	Received

496-P	ANTITHROMBOTIC PROPHYLAXIS IN PREGNANT WOMEN WITH ANTITHROMBIN CONGENITAL DEFICIENCY IS EFFECTIVE IN PREVENTING ADVERSE OUTCOMES	Valerio De Stefano	Received

497-P	HIGH PREVALENCE OF PROTEIN S DEFICIENCY IN THAI POPULATION	Ponlapat Rojnuckarin	Received

498-P	MANAGEMENT OF EXCESSIVE ANTICOAGULATION IN PATIENTS TREATED WITH ACENOCOUMAROL, A VITAMIN K ANTAGONIST.	Jesus Cesar	Received

499-P	GENETIC POLYMORPHISMS RELATED TO HEMOSTASIS AND THEIR ASSOCIATION WITH PRIMARY RECURRENT PREGNANCY LOSS	Elvira Guerra-Shinohara	Received

500-P	HIGH ON-TREATMENT PLATELET REACTIVITY: NOT AN ISOLATED PROBLEM	Martin Jakl	Received

501-P	EVALUATION OF PIVKA-II AS A PREDICTOR MARKER FOR PORTAL VEIN THROMBOSIS IN HEPATOCELLULAR CARCINOMA PATIENTS	Maryse Ayoub	Received

503-P	PERIPHERALLY INSERTED CENTRAL CATHETERS (PICCS) CAN BE SUCCESSFULLY UTILIZED IN HAEMATOLOGICAL PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY OR ALLOGENEIC/AUTOLOGOUS STEM CELL TRANSPLANTATION	Alessandra Malato	Received

504-P	PICC INSERTION AND MANAGEMENT IN HEMATOLOGY PATIENTS: 5 YEARS PROSPECTIVE STUDY THE CAGLIARIS DEPARTMENT OF HAEMATOLOGY	Daniele Derudas	Received

505-P	A NEW SCORE TO DETERMINE THE PROBABILITY OF FINDING AN HLA IDENTICAL UNRELATED DONOR: A VALIDATED EFFICIENT TIME AND COST SAVING METHOD	Mauricette Michallet	Received

506-P	ESTIMATES OF BURDEN OF DISEASE ASSOCIATED WITH MANAGEMENT OF ACUTE MYELOID LEUKEMIA IN UK AND US	Izabela Kucmin	Received

511-P	THE IMPACT OF UNRESTRICTED FUNDING ON HAEMATO-ONCOLOGY TREATMENT CHOICE	Tony Todd	Received

512-P	PATIENT SAFETY AND CLINICAL EFFICIENCY GAINS FOLLOWING IMPLEMENTATION OF AN INTEGRATED HEALTH INFORMATION SYSTEM IN EAST LONDON.	Ciara Freeman	Received

513-P	PHARMACOLOGICAL DRUG EXPENDITURE OF FIRST-LINE INDOLENT NON-HODGKIN LYMPHOMAS IN SPAIN	Juan Manuel Collar	Received

514-P	A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES, UTILITY, RESOURCE USE, AND COST ESTIMATES OF FIRST-LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA	Amin Haiderali	Received

515-P	A COST-BENEFIT ASSESSMENT OF TREATMENT (TX) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: AN EFFICIENCY FRONTIER APPROACH	Shien Guo	Received

518-P	A CALL FOR A STANDARDISED MEASUREMENT OF HAEMOGLOBIN IN THE REPUBLIC OF IRELAND	Jennifer O Sullivan	Received

519-P	DEMAND MANAGEMENT IN A UNIVERSITY LABORATORY IN THE WEST OF IRELAND; THE FINANCIAL BENEFIT OF DISTRIBUTION OF LOCAL GUIDELINES FOR VITAMIN B12 TESTING.	Aoibheann Ni Chonfhaola	Received

617-P	A COHORT STUDY OF POST-RELAPSE/RESISTANCE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	TAMARA INTERMESOLI	Received

618-P	A SEQUENTIAL USE OF TKI, CHEMOTHERAPY AND TRANSPLANT IS ASSOCIATED WITH HIGH COMPLETE REMISSION RATES, DISEASE-FREE AND OVERALL SURVIVAL IN ADULT PH ALL. RESULTS OF THE GIMEMA 0904 PROTOCOL	Sabina Chiaretti	Received

619-P	Comorbidity impacts on complete remission rate in elderly patients with acute lymphoblastic leukemia	Colombe Saillard	Received

620-P	CLL PATIENTS CARRYING 13q DELETION SHOW CLINICAL HETEROGENEITY ACCORDING TO IGHV MUTATIONAL STATUS AND CD38 EXPRESSION	Andrea Visentin	Received

621-P	COMPARABLE OUTCOME OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION AS POST-REMISSION THERAPY IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: INTERIM ANALYSIS OF PROSPECTIVE STUDY	Dae-Young Kim	Received

623-P	MRD LEVEL ANALYSIS IN ADULT ALL PATIENTS. ANALYSIS OF THE CZECH LEUKEMIA STUDY GROUP FOR LIFE (CELL)	Cyril álek	Received

624-P	FLUDARABINE, ARA-C AND LIPOSOMAL DAUNORUBICIN (FLAD) PLUS HEMOPOIETIC STEM CELL TRANSPLANT (HSCT) AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED-REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA.	Marino Clavio	Received

626-P	CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL) : THE BOLOGNA EXPERIENCE	mariachiara abbenante	Received

627-P	ENCOURAGING SURVIVAL IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - RESULTS OF RUSSIAN ACUTE LYMPHOBLASTIC LEUKEMIA (RALL) STUDY GROUP	Elena Parovichnikova	Received

629-P	FOUR YEARS EXPERIENCE WITH HYPER-CVAD TREATMENT OF ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN SWEDEN. POPULATION-BASED DATA.	Piotr Kozlowski	Received

631-P	ADULT MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO THE WHO 2008 CLASSIFICATION A SINGLE CENTER EXPERIENCE	Claudia Moreira	Received

632-P	INTEGRATING ALTERNATIVE DONORS ALLOWS BEST OUTCOMES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTRE STUDY	Barbara Forno	Received

633-P	OBESITY, INSULIN RESISTANCE AND ADIPOKINES IN SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA.	Trkiz Grsel	Received

634-P	ZAP70 GENE EXPRESSION MAY BE A PROGNOSTIC FACTOR FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Bing Xu	Received

638-P	EFFECTS OF PROPHYLACTIC CRANIAL RADIOTHERAPY ON GROWTH HORMONE SECRETION OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA	Gonul Aydogan	Received

639-P	THE IMPACT OF RISK STRATIFICATION BY EARLY BONE-MARROW RESPONSE AND FCM-MRD IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA (A SINGLE INSTITUTION EXPERIENCE IN AZIZA OTHMANA HOSPITAL, TUNIS, TUNISIA).	BEN ABDENNEBI Yosr	Received

641-P	IDENTIFICATION OF NOVEL GENETIC ALTERATIONS BY WHOLE-TRANSCRIPTOME SEQUENCING IN INFANTS WITH CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA	Marco Togni	Received

643-P	ALTERED GENES DOWNSTREAM OF MYCN IN ACUTE MYELOID LEUKEMIA IN ZEBRAFISH BY RETINOIC ACID AND VALPROIC ACID	Li-Jing SHEN	Received

645-P	EXPRESSION, REGULATION AND FUNCTIONAL ROLES OF THE CHEMOKINE RECEPTOR CXCR7 IN ACUTE MYELOID LEUKAEMIA CELLS	Deog-Yeon Jo	Received

646-P	INTERLEUKIN-3 RECEPTOR ALPHA CHAIN (CD123) AS A MARKER FOR LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA AND ITS RELATION TO DISEASE PROGRESSION	Hanan Alwakeel	Received

647-P	EFFECTS OF B-MYB ABERRANT EXPRESSION ON HEMATOPOIETIC PROGENITOR CELL GROWTH AND DETECTION OF GENETIC VARIATIONS THAT MAY MODIFY ITS PROTEIN FUNCTION	SANDRA DOLZ GIMÉNEZ	Received

648-P	MUTATIONS IN RUNX1 AND NPM1 COMBINED WITH IMBALANCES OF CHROMOSOME 21 ARE PREDICTIVE FOR PROGRESSION OF AML	Katya Gancheva	Received

649-P	PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA	Marta Llop García	Received

651-P	CLINICAL AND HEMATOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA WITH REARRANGEMENTS OF EVI1 OR PRDM16	marion eveillard	Received

653-P	IMPACT OF THE E3 UBIQUITIN LIGASE TRAF2 ON TNF-?-INDUCED APOPTOSIS IN A CELL MODEL OF FLT3-ITD-POSITIVE AML	Sebastian Scholl	Received

654-P	PLUMBAGIN ENHANCED TRAIL-INDUCED APOPTOSIS OF KASUMI-1 CELLS IN NOD / SCID MICE	Li-Gen Liu	Received

658-P	IMPLICATIONS OF MIR-10 IN CHEMOTHERAPY RESPONSE OF NPM1 MUTATED AML	ramiro garzon	Received

660-P	SYNERGISTIC EFFECTS OF HSP70 AND HSP90 INHIBITORS IN PRIMARY HUMAN ACUTE MYELOID LEUKEMIA CELLS	Hkon Reikvam	Received

662-P	IMPROVEMENT, BUT STILL POOR PROGNOSIS FOR ESTONIAN PATIENTS COMPARED TO A WELL-DEFINED REGION OF WESTERN SWEDEN, A POPULATION BASED STUDY OF ACUTE DE NOVO LEUKEMIA PATIENTS AGED 16-64 YEARS	Erik Hulegrdh	Received

663-P	PROGNOSTIC IMPACT OF NPM1, IDH1/2 AND DNAH11 GENE MUTATIONS ON NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA PATIENTS NOT HARBORING FLT3/ITD MUTATION	Yeo-Kyeoung Kim	Received

664-P	ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA	Benedetto Bruno	Received

667-P	SYSTEMIC VERSUS LOCALIZED THERAPEUTIC APPROACH FOR ISOLATED MYELOID SARCOMA: META-ANALYSIS OF INDIVIDUAL PATIENT DATA	Darko Antic	Received

669-P	LOW MDR1 AND BAALC EXPRESSION IDENTIFIES A NEW SUBGROUP OF ADULT CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA WITH A FAVORABLE OUTCOME	Xutao Guo	Received

670-P	THE SURFACE MOLECULAR SIGNATURE OF LEUKEMIC CELLS WAS ASSOCIATED WITH NPM1 AND FLT3-ITD MUTATIONS IN ACUTE MYELOID LEUKEMIA	SuJun Gao	Received

671-P	IMPACT OF DAY 14 BONE MARROW EXAMINATION ON RE-INDUCTION DECISION AND PREDICTION OF COMPLETE RESPONSE IN ACUTE MYELOGENOUS LEUKEMIA (AML)	Aamer Aleem	Received

672-P	ADVERSE PROGNOSTIC SIGNIFICANCE OF FLT3 MUTATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA	mirjana mitrovic	Received

675-P	PERIPHERAL BLOOD BLASTS ON DAY 7 OF INITIAL INDUCTION THERAPY PREDICT RESPONSE TO CHEMOTHERAPY AND SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	SuJun Gao	Received

676-P	PROGNOSTIC VALUE OF TH17 CELLS IN ACUTE LEUKEMIA	Manal Salah Eldin	Received

677-P	STUDIES ON BCR AND TLR SIGNALLING IN AGGRESSIVE CLL- THE CASE OF STEREOTYPED SUBSET 1	Ann-Charlotte Bergh	Received

678-P	THE PHOSPHO-PROTEOMIC PROFILE OF CD49D-EXPRESSING CIRCULATING CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IS CONSISTENT WITH CONSTITUTIVE RECEPTORIAL ENGAGEMENT BY BLOOD-BORNE LIGANDS	Dania Benedetti	Received

682-P	SINGLE CELL NETWORK PROFILING (SCNP) ANALYSIS REVEALS DYSFUNCTIONAL SIGNALING WITHIN THE TH17 AXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Michelle Atallah	Received

684-P	EXPRESSION OF ZAP-70 IN CLL ACTIVATES NF-KB SIGNALING	Valerie Pede	Received

685-P	THE PRO-APOPTOTIC MIR-132212/SIRT1/TP53 AXIS IS ACTIVATED UPON B-CELL RECEPTOR TRIGGERING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS	Riccardo Bomben	Received

686-P	HETEROGENEOUS FUNCTIONAL EFFECTS OF CONCOMITANT B CELL RECEPTOR AND TOLL-LIKE RECEPTOR STIMULATION IN CLL WITH MUTATED VERSUS UNMUTATED IMMUNOGLOBULIN GENES	Stavroula Ntoufa	Received

687-P	IGG-SWITCHED CLL HAS A DISTINCT IMMUNOGENETIC SIGNATURE FROM THE COMMON MD VARIANT: ONTOGENETIC IMPLICATIONS	Anna Vardi	Received

689-P	ABERRANT EXPRESSION OF PD-1 IN CHRONIC LYMPHOCYTIC LEUKEMIA IS INDEPENDENT FROM BCR SINGLING AND PDCD1 GENE POLYMORPHISM	Maciej Grzywnowicz	Received

695-P	A NEW ONCOGENIC ROLE OF BCR/ABL-OOF IN CHRONIC MYELOID LEUKAEMIA PATHOGENESIS	Cristina Panuzzo	Received

697-P	MICROVESICLES TRANSCRIPTOME REFLECTS PHYSIOLOGICAL CONDITIONS OF LEUKEMIC PARENTAL CELLS	Gloria Milani	Received

698-P	THE REFERENCE STANDARD FOR BCR-ABL TRANSCRIPT MONITORING IS IMPORTANT TO DEFINE CMR IN CML PATIENTS AND TO TEST THE RQ-PCR METHOD PERFORMANCES	Rodica TALMACI	Received

700-P	IDENTIFICATION AND FOLLOW-UP OF TWO NEW RARE E8A2 BCR-ABL FUSION GENES	Sarah Huet	Received

702-P	EVALUATION OF TOB1 GENE EXPRESSION IN CML PATIENTS AND BLOOD DONOR AND THE EFFECT OF GENE SILENCING IN BCR-ABL CELL LINE	CINTIA MASCARENHAS	Received

705-P	PATTERNS OF ABL KD MUTATION IN ASIAN PATIENTS WITH IMATINIB-RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA	Hawk Kim	Received

706-P	COMPARISON OF NON AUTOMATED BCR-ABL1 RT-QPCR WITH THE XPERT BCR-ABL MONITOR TM ASSAY	Stephanie Dulucq	Received

711-P	LONG-TERM SURVIVAL OUTCOME AND PROGNOSIS IN 2277 PATIENTS WITH CHRONIC MYELOID LEUKAEMIA ALLOCATED TO FIRST-LINE IMATINIB TREATMENT NEW RESULTS FROM THE EUTOS IN-STUDY REGISTRY	Markus Pfirrmann	Received

713-P	DEFINING LOW AND UNDETECTABLE LEVELS OF DISEASE IN CHRONIC MYELOID LEUKAEMIA: PROGRESS TOWARDS STANDARDISATION IN EUROPE	Helen White	Received

714-P	CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES (BCR-ABL1 =10 AT 3 MONTHS AND =1 6 MONTHS) AS A PREDICTOR FOR LONG-TERM OUTCOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB	Sung-Eun Lee	Received

716-P	HEPATITIS B VIRUS REACTIVATION IN CHRONIC MYELOID LEUKEMIA TREATED WITH VARIOUS TYROSINE KINASE INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY	Sung-Hyun Kim	Received

717-P	EARLY AND DEEP RESPONSES TO IMATINIB PREDICT NOT ONLY COMPLETE MOLECULAR RESPONSE BUT ALSO THE PROBABILITY FOR MAINTAINING THE RESPONSE.	Valentín García-Gutiérrez	Received

720-P	IN CML PATIENTS TREATED FRONTLINE WITH IMATINIB, WITH A BCR-ABL RATIO HIGHER THAN 10 AT 3 MONTHS, THE CHANGE TO A 2ND GTKI IS ASSOCIATED WITH IMPROVEMENT OF CYTOGENETIC RESPONSE, BUT NOT WITH MMR	LUIS FELIPE CASADO MONTERO	Received

721-P	CLINICAL AND BIOLOGICAL FEATURES OF BLAST CRISIS (BC) IN PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA (CML) IN THE TKIS ERA: EXPERIENCES IN CLINICAL PRACTICE	Antonella Russo Rossi	Received

722-P	REVERSIBLE LYMPH NODE FOLLICULAR HYPERPLASIA ASSOCIATED WITH DASATINIB TREATMENT FOR CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE	Clémence Roux	Received

723-P	Descriptive study of CML patients in major molecular response (MMR) with an evaluation of clinical and therapeutic characteristics leading to the conversion into a complete molecular response (CMR)	Mauricette Michallet	Received

726-P	EUTOS CML PROGNOSTIC SCORING SYSTEM PREDICTS ELN-BASED EVENT-FREE SURVIVAL BETTER THAN EURO/HASFORD AND SOKAL SYSTEMS IN CHRONIC PHASE CML PATIENTS RECEIVING FRONTLINE IMATINIB MESYLATE	Nilgun Sayinalp	Received

728-P	BONE MARROW IMAGING OF HUMERAL AND FEMORAL MARROW BY MULTI-DETECTOR COMPUTED TOMOGRAPHY IN PATIENTS WITH APLASTIC ANEMIA AND HYPOPLASTIC MDS	Tomotaka Ugai	Received

730-P	BONE MARROW SCREENING FOR MYELODYSPLASIA-RELATED CHANGES AND ABERRANT LYMPHOID POPULATIONS USING ONE TUBE, FOURTEEN ANTIBODY-TEN COLOR FLOW CYTOMETRY PANEL	Anna Porwit	Received

731-P	PLATELET COUNT AND TRANSFUSION-DEPENDENCY AFFECT OVERALL SURVIVAL IN PATIENTS WITH REFRACTORY ANEMIA WITH RING SIDEROBLASTS AND THROMBOCYTOSIS (RARS-T)	Gregory Kaufman	Received

732-P	A PROSPECTIVE PHASE II STUDY OF ATG-CYCLOSPORINE A FOR ADULT SEVERE APLASTIC ANEMIA: MEDIAN 8-YEAR FOLLOW-UP DATA	Hawk Kim	Received

733-P	IMPACT OF THE PROLIFERATION INDEX OF SPECIFIC BONE MARROW CELL COMPARTMENTS FROM MYELODYSPLASTIC SYNDROMES IN THE MONITORIZATION OF THE DISEASE: A PILOT STUDY	Sergio Matarraz	Received

734-P	BENEFITS OF THE USE OF AZACITDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY	Claudio Cerchione	Received

736-P	LONG DURATION OF RESPONSE TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES. MULTICENTER RETROSPECTIVE STUDY OF 36 PATIENTS	Carlo Finelli	Received

737-P	PROLONGED LOW-DOSE AZACITIDINE SCHEDULE IN HIGH-RISK MDS PATIENTS: LONG TERM EFFICACY AND RELATIONSHIP WITH MOLECULAR RESPONSE	cristina clissa	Received

739-P	REAL WORLD USE OF AZACITIDINE IN ELDERLY PATIENTS WITH MDS/AML THE SCOTTISH EXPERIENCE	Kirstin Lund	Received

740-P	MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE	Dawn Lee	Received

741-P	ANALYSIS OF RESPONSE TO ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN 114 MYELODYSPLASTIC SYNDROME (MDS) PATIENTS FROM REGISTRO CAMPANO DELLE MIELODISPLASIE	Claudio Cerchione	Received

743-P	RISK SCORING SYSTEM USING IPSS-R, LDH AND PERFORMANCE STATUS TO PREDICT THE OUTCOMES OF PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS	Sang Kyun Sohn	Received

744-P	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE: DIAGNOSTIC AND CLASSIFICATION OF 103 BRAZILIAN PATIENTS	ANA PAULA AZAMBUJA	Received

745-P	ERYTHROPOIETIC ASPECTS IN MDS PATIENTS RESPONDERS TO ESAS TREATMENT	Claudio Cerchione	Received

746-P	COMPARISON OF IPSS AND R-IPSS IN A SINGLE UNIT PATIENT COHORT	Francesca Pierdomenico	Received

747-P	DOES REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) HAVE ANY IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS?	Zhenwei Teo	Received

749-P	NEW STRATEGIES OF ANALYSIS WITH FLOW CYTOMETRY FOR THE DIAGNOSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA	Paola Beneit	Received

750-P	FREQUENT MUTATION OF THE MYD88 GENE IN MACROGLOBULINEMIA	Naoki Mori	Received

751-P	THE ROLE OF FLT3-LIGAND IN THE PROGRESSION OF MULTIPLE MYELOMA; FLT3-LIGAND RELEASED FROM BONE MARROW STROMAL CELLS ACTIVATED PI3K/AKT PATHWAY AND WNT SIGNALING	Sung-Soo Yoon	Received

752-P	CIRCULATING MICRORNA AS POTENTIAL BIOMARKERS OF MGUS AND MM	Lenka Kubiczkova	Received

754-P	DEF124B, A MEMBER OF THE ?-DEFENSINS, IS DOWNREGULATED IN DIFFERENTIATING OSTEOBLASTS BY EXPOSURE TO IMIDS AND MAY MEDIATE THE SUPPRESSIVE EFFECT OF THESE AGENTS ON OSTEOGENESIS	Heinz Ludwig	Received

755-P	IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 IN MYELOMA	Jacqueline Noll	Received

757-P	NEUTROPHILS ARE IMPAIRED IN MULTIPLE MYELOMA BUT NOT IN MGUS	ALESSANDRA ROMANO	Received

758-P	IDENTIFICATION OF INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7 (IGFBP7) AS TUMOR SUPPRESSOR IN MULTIPLE MYELOMA LINKED TO THE PRESENCE OF OSTEOLYTIC LESIONS AND OVERALL SURVIVAL	Heinz Ludwig	Received

759-P	HIGH RISK CYTOGENETIC ABNORMALITIES AND PLASMA CELLS PHENOTYPE INDUCE SIGNIFICANT ALTERATIONS IN BONE MARROW B-CELL COMPARTMENTS IN MONOCLONAL GAMMOPATHIES	Sofia Ramos	Received

760-P	ANGIOPOIETIN-2 AND MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA HAVE DUAL EFFECT ON BONE INVOLVEMENT AND ANGIOGENESIS IN MULTIPLE MYELOMA	George Tsirakis	Received

761-P	GENE EXPRESSION OF BONE MODULATORS IN WHOLE BONE MARROW BIOPSIES IN CORRELATION TO DYNAMIC BONE MARKERS IN MULTIPLE MYELOMA BONE DISEASE	Ida Bruun Kristensen	Received

762-P	P15 AND DAPK METHYLATION IN MULTIPLE MYELOMA AND MGUS: COMPARISON BETWEEN BONE MARROW AND PERIPHERAL BLOOD	Catarina Geraldes	Received

768-P	SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL	Paul Richardson	Received

769-P	CONSOLIDATION WITH HD- MELPHALAN AND AUTOTRANSPLANT (ASCT) AFTER SECOND-LINE TREATMENT INCREASES RESPONSE RATE AND PROGRESSION-FREE SURVIVAL IN MYELOMA PATIENTS RELAPSED AFTER FIRST-LINE ASCT	Claudia Crippa	Received

770-P	TOTAL THERAPY 3 (TT3)-BASED TREATMENT FOR MULTIPLE MYELOMA AN EXTENDED SINGLE CENTER EXPERIENCE	Eli muchtar	Received

772-P	MM-008: A PHASE 1 TRIAL EVALUATING PHARMACOKINETICS AND TOLERABILITY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH RENAL IMPAIRMENT	Jeffrey Matous	Received

773-P	CAUSES OF DEATH 30 AND 180 DAYS AFTER DIAGNOSIS IN NON-HDT TREATED DANISH MULTIPLE MYELOMA PATIENTS: A STUDY FROM THE DANISH MYELOMA STUDY GROUP	Morten Orebo Holmstrm	Received

774-P	PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)	Elizabeth Bilotti	Received

777-P	THE UK LENALIDOMIDE TREATMENT CONTINUATION SCHEME: TRENDS OF LONG-TERM TREATMENT IN A CLINICAL SETTING	Cathy Williams	Received

778-P	THE EFFICACY AND SAFETY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IS NOT IMPACTED BY AGE IN PATIENTS WITH ADVANCED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: MM-002 SUBGROUP ANALYSIS	Sundar Jagannath	Received

779-P	PROMISING ROLES OF AMIFOSTINE AS PROPHYLACTIC AGENTS AGAINST BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY	Meiyun Fang	Received

780-P	MP VS MPT IN FIRST TO FOURTH LINE OF TREATMENT IN MULTIPLE MYELOMA PATIENTS	Johan Lund	Received

781-P	CAN NOVEL AGENTS OVERCOME THE NEGATIVE PROGNOSTIC IMPACT OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA? - A POPULATION BASED STUDY INCLUDING 1538 PATIENTS	Katarina Uttervall	Received

784-P	SESTAMIBI TECHNETIUM-99M BONE MARROW SCAN IS ABLE TO PREDICT OVERALL DISEASE OUTCOME AND MORTALITY COMPARED TO WHOLE BODY MAGNETIC RESONANCE IMAGING IN MULTIPLE MYELOMA	Alhossain Khalafallah	Received

788-P	ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	Michel Delforge	Received

789-P	VTD CONSOLIDATION, WITHOUT BISPHOSPHONATES, REDUCES BONE RESORPTION AND IS ASSOCIATED WITH A VERY LOW INCIDENCE OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA POST-ASCT	Dimitrios Christoulas	Received

790-P	IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS	Michele Cavo	Received

791-P	TREATMENT WITH BORTEZOMIB-BASED REGIMENS IMPROVES OVERALL RESPONSE AND PREDICTS FOR SURVIVAL IN PATIENTS WITH PRIMARY OR SECONDARY PLASMA CELL LEUKEMIA: ANALYSIS OF THE GREEK MYELOMA STUDY GROUP	Eirini Katodritou	Received

792-P	EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED DATA ON SAFETY AND SPM INCIDENCE IN PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB	Michele Cavo	Received

794-P	CIRCULATING SOLUBLE RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B LIGAND (SRANKL) AND C-C MOTIF LIGAND-3 (CCL-3) LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH WALDENSTROMS MACROGLOBULINEMIA	Dimitrios Christoulas	Received

795-P	RESULTS OF THE DUTCH COMMUNITY BASED TRIAL VALEO WITH BORTEZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS	Richard Milek	Received

797-P	HIGH RISK CYTOGENETICS, ELEVATED LDH AND ISS-3 IDENTIFY A SUBGROUP OF MYELOMA PATIENTS WITH VERY POOR PROGNOSIS	Efstathios Kastritis	Received

798-P	BONE BIOMARKERS ARE USEFUL IN MONITORING MYELOMA BONE DISEASE AND AS EARLY PREDICTOR FOR RELAPSE DISEASE IN MULTIPLE MYELOMA	Kay Reen Ting	Received

799-P	EX VIVO PHARMACOLOGICAL EVALUATION OF 19 DRUGS IN AN AVERAGE OF 50 MULTIPLE MYELOMA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY	Belén Liébana	Received

800-P	THE IMPACT OF 8 GY ONE FRACTION RADIOTHERAPY ON PAIN RELIEF AND RECALCIFICATION IN MULTIPLE MYELOMA PATIENTS WITH PAINFUL BONE DESTRUCTIONS.	Milda Rudzianskiene	Received

801-P	RESULTS OF LENALIDOMIDE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN A REAL WORLD SETTING: FEASIBILITY AND FACTORS CONTRIBUTING TO LONG TREATMENT DURATION	Gunter Derigs	Received

802-P	THE PRESENCE OF IMMUNOPHENOTYPIC ALTERATIONS IN BONE MARROW CELLS OTHER THAN PLASMA CELLS FROM MULTIPLE MYELOMA PATIENTS PREDICTS FOR MYELODYSPLASIA-ASSOCIATED CYTOGENETIC ABNORMALITIES	Sergio Matarraz	Received

804-P	FLOW CYTOMETRIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: A COMPARISON BETWEEN FLOW CYTOMETRIC IMMUNOPHENOTYPING AND CYCLOSCOPE-MG.	GIACOMA DE TULLIO	Received

805-P	NUMBER OF ADVERSE CYTOGENETIC LESIONS DETECTED BY FISH IS ASSOCIATED WITH PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-BASED REGIMENS	Norbert Grzasko	Received

806-P	EVALUATION OF TNF SUPERFAMILY MOLECULES IN MULTIPLE MYELOMA PATIENTS: CORRELATION WITH BIOLOGICAL AND CLINICAL FEATURES.	Bolkun Lukasz	Received

807-P	TOXICITY PROFILE DURING TREATMENT WITH BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Heinz Ludwig	Received

808-P	VALUE OF WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IN THE STUDY OF MONOCLONAL GAMMOPATHIES AND CORRELATION WITH BONE-RELATED CYTOKINES	RAFAEL MARTOS MARTINEZ	Received

809-P	THE COMBINATION OF BORTEZOMIB AND DEXAMETHASONE (VD) ALONG WITH ZOLEDRONIC ACID INCREASES BONE MINERAL DENSITY (BMD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY	Dimitrios Christoulas	Received

810-P	LONG TERM THERAPY WITH LENALIDOMIDE DOES NOT SIGNIFICANTLY AFFECT THE CELLULAR COMPOSITION OF THE BONE MARROW	Annamaria Brioli	Received

811-P	A RETROSPECTIVE REVIEW OF THE INCIDENCE OF CONTRAST INDUCED NEPHROPATHY IN THE MYELOMA SETTING	Maeve Crowley	Received

812-P	EFFECTS OF BORTEZOMIB ON RENAL IMPAIRMENT MULTIPLE MYELOMA PATIENTS	wenming chen	Received

813-P	THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS	Jian Hou	Received

816-P	LONG TERM FOLLOW-UP OF TREATMENT WITH IMATINIB IN EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS WITH PDGFR REARRANGEMENTS IN ADVANCED PHASE	Georgia Metzgeroth	Received

819-P	HOW MANY CHILDREN WITH THROMBOCYTOSIS OF UNDEFINED ORIGIN HAVE A MYELOPROLIFERATIVE NEOPLASM?	Maria Luigia Randi	Received

821-P	CLINICAL FEATURES OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPLICATED BY PORTAL HYPERTENSION	Matthew Yan	Received

822-P	EOSINOPHILIA IN ROUTINE BLOOD SAMPLES AND THE SUBSEQUENT RISK OF HEMATOLOGICAL MALIGNANCIES AND DEATH	Christen Andersen	Received

823-P	CHRONIC MYELOPROLIFERATIVE NEOPLASMS REVEAL INCREASED RISK OF OSTEOPOROTIC FRACTURES	Sarah Farmer	Received

824-P	DETERMINANTS AND FREQUENCY OF THROMBOTIC AND BLEEDING COMPLICATIONS IN AN ITALIAN COHORT OF 88 PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN): THE ROLE OF ADAMTS-13 AND VWF ACTIVITIES	Augusto B Federici	Received

825-P	INTERNATIONAL PROGNOSTIC SCORE FOR ESSENTIAL THROMBOCYTHEMIA (IPSET) AND IPSET-THROMBOSIS ONE CENTRE ANALYSIS	TERESA GARRIDO	Received

826-P	BCR/ABL EXPRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS	Laura Kesaeva	Received

827-P	A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)	Jessica Litvan	Received

829-P	ADDITION OF THE DEGREE OF BONE MARROW FIBROSIS TO IPSS IN NEW SCORING SYSTEM IMPROVES PREDICTION OF SURVIVAL IN PRIMARY MYELOFIBROSIS	Danijela Lekovic	Received

830-P	CONTRIBUTION OF SNP ARRAYS TO THE DIAGNOSIS AND PROGNOSIS OF CMML. A STUDY OF PATIENTS WITH LOW RISK CYTOGENETIC FEATURES AND CASES WITH ABSENCE OF METAPHASES	Laura Palomo	Received

832-P	HIGHLY SPECIFIC QPCR ASSAYS USING CONSENSUS LNA PROBE FOR THE DETECTION OF t(11;14) AND t(14;18) IN NON-HODGKIN LYMPHOMA WITH A SENSITIVITY OF 10-5 FOR QUANTIFICATION OF MINIMAL RESIDUAL DISEASE	Camilla Darum Srensen	Received

834-P	NR4A1 MEDIATED APOPTOSIS SUPPRESSES LYMPHOMAGENESIS IN A XENOGRAFT MOUSE MODEL	Alexander Deutsch	Received

835-P	EZH2 EXPRESSION DETERMINED BY IMMUNOHISTOCHEMISTRY DOES NOT CORRELATE WITH THE PRESENCE OF EZH2 MUTATIONS IN A SERIES OF DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL)	Mar Garcia	Received

836-P	DLBCL BIOLUMINESCENT XENOGRAFT MODEL FOR NON-INVASIVE FOLLOW-UP OF ANTITUMOR EFFECT	María José Moreno Jiménez	Received

837-P	BLOOD AND LYMPHATIC MICROENVIRONMENT, MACROPHAGE COMPONENT AS PROGNOSTIC MARKERS IN FOLLICULAR LYMPHOMA	Ekaterina Nesterova	Received

841-P	IDENTIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) SUBTYPES DEFINED BY THE EXPRESSION OF STROMAL PROTEINS AND THEIR ASSOCIATION WITH MICRORNAS INVOLVED IN ANGIOGENESIS	Natália Borges	Received

842-P	DISTINCT GENE EXPRESSION PROFILES IN A CANINE MODEL OF HUMAN DLBCL	Geertruy te Kronnie	Received

844-P	CLINICAL SYMPTOM OR SIGN-DIRECTED SURVEILLANCE CAN BE MORE USEFUL TO DETECT RELAPSE COMPARED TO ROUTINE IMAGING IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AFTER COMPLETE REMISSION	Junshik Hong	Received

845-P	VIROLOGICAL SUCCESS IS ASSOCIATED WITH FAVORABLE PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS.	Jean Marie Michot	Received

847-P	HIGH-DOSE METHOTREXATE, HIGH-DOSE CYTARABINE AND TEMOZOLOMIDE FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	maher salamoon	Received

850-P	LENALIDOMIDE PLUS RITUXIMAB-CHOP21 IN ELDERLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA IS PROMISING: LONG TERM RESULTS OF THE PHASE II REAL07 STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)	Annalisa Chiappella	Received

851-P	PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)	Pam Milner	Received

852-P	PROSPECTIVE COHORT STUDY FOR SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CHOP	Seok Jin Kim	Received

853-P	INTERIM PET-CT SCAN AFTER 2 CYCLES SUCCESSFULLY PREDICTS OUTCOME IN DLBL BUT INTRODUCES SIGNIFICANT SELECTION BIAS.	Nicholas Grigoropoulos	Received

854-P	STAGING NEWLY DIAGNOSED LYMPHOMAS: COMPARISON BETWEEN WHOLE BODY-MRI/DWIBS AND 18FDG-PET/CT	Carla Minoia	Received

855-P	CENTRAL NERVOUS SYSTEM RELAPSE IN NON HODGKIN LYMPHOMA: PROGNOSTIC FACTORS AND OUTCOME IN A COHORT OF 304 PATIENTS	Juanjosé Alonso	Received

856-P	LYMPHOCYTE COUNT AT DIAGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA IN THE ERA OF IMMUNOCHEMOTHERAPY WITH RITUXIMAB: IS 1000/MM3 STILL THE BEST CUT-OFF VALUE TO USE TO DEFINE LYMPHOPENIA ?	Alessia Bari	Received

859-P	PROGNOSTIC FACTORS IN VERY OLD PATIENTS (= 75 YEARS) WITH FOLLICULAR LYMPHOMA: A MULTICENTRE RETROSPECTIVE STUDY	Anne Parcelier	Received

860-P	EFFICACY AND SAFETY OF LENALIDOMIDE WITH/WITHOUT RITUXIMAB OR STEROIDS IN HEAVILY PRETREATED NON-HODGKINS B-CELL LYMPHOMAS: RESULTS OF A RETROSPECTIVE STUDY	ANNALISA CHIAPPELLA	Received

862-P	SERUM FREE LIGHT CHAINS LEVELS IN PATIENTS WITH HIV-RELATED LYMPHOMA ARE LOWER AT COMPLETE RESPONSE THAN AT DIAGNOSIS	Maria Joao Baptista	Received

863-P	PROGNOSTIC RELEVANCE OF FDG-PET IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA	Gayane Tumyan	Received

864-P	FC-GAMMA-RECEPTOR IIIA POLYMORPHISM AND GENE EXPRESSION PROFILE DO NOT INFLUENCE TREATMENT OUTCOMES AND SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP PROTOCOL	Laszlo Varoczy	Received

865-P	INTENSIFIED PROGRAM INCLUDING BENDAMUSTINE, HIGH DOSE THERAPY AND AUTOGRAFT FOR PATIENTS WITH RELAPSED OR RESISTANT FOLLICULAR NON HODGKIN LYMPHOMA: RESULTS FROM AN EXPLORATORY GITIL STUDY	Caterina Patti	Received

866-P	THE INTENSITY AND DURATION OF PAIN ASSOCIATED WITH TREPHINE BIOPSY	Waleed Ghanima	Received

869-P	THE ROLEOF PET/CT FOR EVOLUATION OF THE BONE MARROW INVOLVEMENT IN LYMPHOMA PATIENTS	asu fergun yilmaz	Received

870-P	ANALYSIS OF THE BONE MARROW INFILTRATION IN A GROUP OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA BY COMPARING BONE MARROW BIOPSY AND 18F-FDG PET/CT	Paula César	Received

871-P	COMPARISONS OF B-CELL AND T-CELL LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	Jui-Ting Yu	Received

873-P	HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION	Eisei Kondo	Received

874-P	A MULTICENTRE REVIEW OF THE OUTCOMES OF PATIENTS ABOVE THE AGE OF 75 WITH PRIMARY DIFFUSE LARGE B CELL LYMPHOMA	Vikramajit Singh	Received

875-P	HUMAN CORD BLOOD CD45 CELLS PROTECT MICE BRAIN AFTER CLOSED HEAD INJURY	Hadar Arien-Zakay	Received

876-P	PYROSEQUENCING IS A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY	Federica Cattina	Received

878-P	DIFFERENT DOSE OF ATG INDUCTION THERAPY IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: LONG TERM EFFECT ON TH17 AND CONVENTIONAL T CELLS, NOT ON NK RESPONSES	Xiang-Yu Zhao	Received

879-P	CIRCULATING ENDOTHELIAL CELLS (CEC) ARE A RELIABLE AND DYNAMIC BIOMARKER OF ACUTE GVHD (AGVHD) IN PATIENTS UNDERGOING ALLOGENEIC STEM CELLS TRANSPLANTATION.	Andrea Di Palma	Received

880-P	EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION ON THE EXPRESSION OF REGULATORY GAMMA DELTA T CELLS	Qifa Liu	Received

883-P	PARALEL STUDY OF CHIMERISM AFTER ALLOGENIC HAEMTOPOIETIC STEM CELL TRANSPLANTATION MONITORED BY TWO DIFFERENT MOLECULAR METHODS	Eva Hanusovska	Received

884-P	VENO-OCCLUSIVE DISEASE MAY DEVELOP IN SECONDARY IRON OVERLOADED MICE AFTER TOTAL BODY IRRADIATION.	Dae Chul Jeong	Received

887-P	STUDY OF SOLUBLE HLA-G LEVEL DYNAMICS IN HEMATOLOGICAL PATIENTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION	Elena Ribakovsky	Received

889-P	CONTROLLED EPSTEIN-BARR VIRUS REACTIVATION AFTER ALLOGENIC TRANSPLANTATION IS ASSOCIATED WITH IMPROVED SURVIVAL ASSOCIATED TO AN EXPANSION OF NATURAL KILLER CELLS (NK).	JEAN FRANCOIS ROSSI	Received

890-P	MYELOABLATIVE FLUDARABINE PLUS BUSULFAN IV (FB4) REGIMEN COMPARES FAVOURABLY WITH CYCLOPHOSPHAMIDE PLUS BUSULFAN (BUCY) IN PATIENTS UNDERGOING ALLO-SCT FOR MYELOID MALIGNANCY	Valerie COITEUX	Received

891-P	LONG-TERM OUTCOME (BEYOND 10 YEARS) AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION WITH REDUCED-INTENSITY COMPARED TO MYELOABLATIVE CONDITIONING; SIMILAR SURVIVAL BUT DIFFERENT PATTERN OF LATE EVENTS	Avichai Shimoni	Received

892-P	HOW MANY AML PATIENTS DO RECEIVE EARLY ALLOGENEIC BONE MARROW TRANSPLANT AND WHICH TRANSPLANT IS PERFORMED? REAL LIFE DATA FROM GENOVA ACUTE LEUKEMIA REGISTRY (REGAL).	Marino Clavio	Received

893-P	THE MANAGEMENTS OF EBV-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Qifa Liu	Received

894-P	ASSOCIATION OF HLA POLYMORPHISMS WITH EPSTEIN-BARR VIRUS INFECTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	Qifa Liu	Received

895-P	PERFORMANCE OF FECAL CALPROTECTIN FOR THE DIAGNOSIS AND FOLLOW UP OF ACUTE GASTRO-INTESTINAL GRAFT VERSUS HOST DISEASE	Marta Lisa Battista	Received

896-P	IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA	Luisa Giaccone	Received

898-P	THREE DAYS BUSULFAN ASSOCIATED WITH FLUDARABINE AND ANTITHYMOGLOBULINE CONDITIONING: IS IT SAFE?	Sylvain Chantepie	Received

899-P	IMPROVED OUTCOME WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A POOR PROGNOSTIC SUBGROUP OF PATIENTS WITH MIXED-LINEAGE-LEUKEMIAREARRANGED LEUKEMIA: RESULTS FROM A SINGLE-CENTER PROSPECTIVE STUDY	yu wang wang	Received

902-P	MOBILIZATION AND ENGRAFTMENT OF PERIPHERAL BLOOD STEM CELLS IN RELATED HEALTHY DONORS OLDER THAN 55 YEARS	Cristina Motlló	Received

903-P	EFFICACY OF ORAL BUDESONIDE FOR GASTROINTESTINAL GRAFT VERSUS HOST DISEASE IN HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS	Mui Fong Chong	Received

905-P	MYELOABLATIVE CONDITIONING REGIMEN WITHOUT ATG AND TBI IN SINGLE UNIT UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH HEMATOLOGIC MALIGNANCIES	Juan Tong	Received

907-P	IMPACT OF INAPPROPRIATE MICAFUNGIN PROPHYLAXIS IN A BONE MARROW TRANSPLANTATION (BMT) UNIT ON THE OUTCOME OF CANDIDIASIS AND ON THE EMERGENCE OF ECHINOCANDIN-RESISTANT CANDIDA KRUSEI ISOLATES	Emmanuelle Tavernier	Received

909-P	SIMILAR OUTCOMES BETWEEN YOUNGER AND OLDER AGE GROUP IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO RECEIVED HLA-MATCHED SIBLING TRANSPLANTS WITH FLUDARABINE-BASED CONDITIONING	Seung Hwan Shin	Received

910-P	POORER OUTCOME AFTER CORD BLOOD THAN AFTER MATCHED RELATED OR UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION PREPARED WITH REDUCED TOXICITY CONDITIONING FOR HIGH RISK ACUTE MYELOID LEUKEMIA	devillier raynier	Received

912-P	KIR-LIGAND INCOMPATIBILITY IN THE GRAFT-VERSUS-HOST DIRECTION DID NOT AFFECT OUTCOMES OF SINGLE UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT ATG FOR ACUTE LEUKEMIA IN COMPLETE REMISSION	Junji Tanaka	Received

914-P	PROGNOSTIC IMPACT OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS WITH MYELOID NEOPLASMS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION A SINGLE INSTITUTION SERIES	Desire Gijima	Received

915-P	IN VIVO T-CELL DEPLETION WITH LOW-DOSE ANTITHYMOCYTE GLOBULIN TO REDUCE ACUTE GVHD IN UNRELATED DONOR STEM CELL TRANSPLANT FOR PATIENTS WITH SEVERE APLASTIC ANEMIA	Sung-Eun Lee	Received

916-P	IMPACT OF ABO INCOMPATIBILITY ON UNRELATED CORD BLOOD TRANSPLANTATION	Yao Wen	Received

917-P	SECONDARY ANTIFUNGAL PROPHYLAXIS BASED ON RESPONSE TO INITIAL ANTIFUNGAL THERAPY FOR PATIENTS WITH A HISTORY OF INVASIVE PULMONARY ASPERGILLOSIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	Qifa Liu	Received

918-P	A MONOCLONAL PROTEIN FOUND IN RELATED STEM CELL DONORS: ARE WE DOING IT RIGHT?	Nicolette Tiren-Verbeet	Received

919-P	TBI AND CYCLOPHOSPHAMIDE PLUS ATG IS WELL TOLERATED AND EFFECTIVE AS A PREPARATIVE REGIMEN FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION	Haixia Fu	Received

920-P	HIGH LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR IS ASSOCIATED WITH INCREASED RELAPSE RATE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Ivan Moiseev	Received

921-P	CLINICAL IMPACT OF ENGRAFTMENT SYNDROME IN ADULT PATIENTS WHO RECEIVED ALLOGENEIC STEM CELL TRANSPLANTATION	Hiroaki Shimizu	Received

924-P	THERAPEUTIC APPROACH TO RELAPSE OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Claudia Moreira	Received

925-P	IMPACT OF THE 2009 UK UMBILICAL CORD BLOOD TRANSPLANT CONSENSUS STATEMENT ON PRACTICE AND OUTCOMES AT A SINGLE TRANSPLANT CENTRE	chloe anthias	Received

926-P	CMV-SPECIFIC CD8 T-CELL IMMUNE RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION MONITORED BY HLA-MULTIMERS	EDUARDO OLAVARRIA	Received

927-P	IDENTIFICATION OF THE EARLIEST BRANCH POINT FOR MYELO-ERYTHROID DEVELOPMENT IN ADULT HEMATOPOIESIS	Kohta Miyawaki	Received

932-P	Studies of JARID1B in Hematopoiesis Using Gene Knockdown and Overexpression Assay	Jingxuan Zhang	Received

933-P	ROLE OF BMI-1 IN NORMAL MOUSE HEMATOPOIETIC STEM CELLS AND LEUKEMIC CELLS	Yuk Man Lam	Received

934-P	CONNECTIVE TISSUE GROWTH FACTOR (CTGF) CONFERS CELL ADHESION-MEDIATED DRUG-RESISTANCE (CAM-DR) IN ACUTE MYELOID LEUKEMIA	Saskia Pante	Received

935-P	HUMAN BONE MARROW ADIPOCYTES MAINTAIN THE SURVIVAL AND DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS	Giulia Maurizi	Received

937-P	ANALYSIS OF HUMAN ENDOSTEAL HSC NICHE; A NOVEL POPULATION WITH HIGH EXPRESSION OF CD34 AND ESAM IS ADJACENT TO TRABECULAR AREAS OF HUMAN BONE MARROW	MICHIKO ICHII	Received

938-P	HEAD-TO-HEAD COMPARATIVE STUDY OF WHARTONS JELLY AND BONE MARROW MESENCHYMAL STEM CELLS	Charalampos Pontikoglou	Received

939-P	ALTERATION IN GENE EXPRESSION PATTERN IN STROMAL PRECURSOR CELLS OF PATIENTS BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION	Irina Shipounova	Received

940-P	ROLE OF BONE MARROW STROMAL CELLS IN THE REGULATION OF HUMAN EARLY LYMPHOPOIESIS	Kohshi Ohishi	Received

941-P	DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA	Francesco Dalò	Received

943-P	UMBILICAL CORD MESENCHYMAL STEM CELLS WITH IMPROVED SUPPORT FOR HEMATOPOIETIC STEM CELL EXPANSION.	Pavel Butylin	Received

944-P	ENDOTHELIAL CELLS EXPRESSING CONSTITUTIVELY ACTIVE AKT1 ARE CAPABLE OF RECONSTITUTING OF VASCULAR NICHE IN VITRO.	Pavel Butylin	Received

945-P	CHEMOKINE SIGNALLING REGULATES HAEMOPOIETIC STEM CELL PROPERTIES	Amy Sinclair	Received

947-P	MONOALLILIC MUTATIONS OF FHL-RELATED GENES PREDISPOSE TO MACROPHAGE ACTIVATION SYNDROME	Elena Sieni	Received

949-P	COMBINED APPLICATION OF MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION AND FLUORESCENCE IN SITU HYBRIDIZATION TO DETECT CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA	Donat Alpar	Received

950-P	COMPARISON OF MICROARRAY-BASED GENOMIC PROFILING AND MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) FOR THE DETECTION OF CLINICALLY RELEVANT GENETIC LESIONS, INCLUDING IKZF1, IN ALL	Marian Stevens-Kroef	Received

955-P	ARRAY-BASED GENOMIC PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IDENTIFIES HIGHER NUMBER OF PROGNOSTIC RELEVANT GENOMIC ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES	Marian Stevens-Kroef	Received

956-P	DEREGULATION OF STEM CELL FACTOR (SCF)-AKT-S6 PATHWAY IN DIAGNOSTIC AML SAMPLES IS ASSOCIATED WITH DISEASE-FREE SURVIVAL: RESULTS OF A VERIFICATION STUDY	Michelle Atallah	Received

957-P	HIGH-RESOLUTION GENOMIC PROFILING IN MULTIPLE MYELOMA IDENTIFIES RECURRENT PROGNOSTIC RELEVANT COPY NUMBER ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES	Marian Stevens-Kroef	Received

959-P	IMPORTANCE OF MICROARRAY ANALYSIS AS A PROGNOSTIC CLINICAL TOOL IN CHRONIC LYMPHOCYTIC LEUKEMIA	Nolwen Prie	Received

961-P	CHARACTERISTICS OF VARIANT AND ADDITIONAL CYTOGENETIC ABNORMALITIES IN ACUTE MYELOID LEUKEMIA WITH RECURRENT GENETIC ABNORMALITIES	Eunhae Cho	Received

962-P	MUTATIONAL STUDY OF DNMT3A IN ACUTE MYELOID LEUKEMIA	Seung Hwan Oh	Received

965-P	EX VIVO SENSITIVITY AND RESISTANCE MECHANISMS TO CLOFARABINE IN CHILDHOOD ACUTE LEUKEMIA	Baleydier Frederic	Received

967-P	TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS	Athina Giannoudis	Received

968-P	TARGETING THE DBC1-SIRT1-P53 AXIS IS A PROMISING THERAPEUTIC STRATEGY IN FLT3-ITD-POSITIVE AML	Daniel Sasca	Received

969-P	TRANSCRIPTIONAL PROGRAMMES ASSOCIATED WITH EVI1 MEDIATED CHEMOTHERAPY RESISTANCE OF HUMAN MYELOID CELLS	Rotraud Wieser	Received

970-P	KNOCKDOWN OF NUCLEOPHOSMIN BY RNA INTERFERENCE REVERSES MULTIDRUG RESISTANCE IN RESISTANT LEUKEMIC HL-60 CELLS	Jianda Hu	Received

972-P	POLYMORPHISMS OF MULTIDRUG RESISTANCE TRANSPORTER (ABCG2 AND ABCB1) GENES IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA	Hajnalka Andrikovics	Received

976-P	EVIDENCE THAT THE PREGNANE X AND RETINOID RECEPTORS PXR, RAR AND RXR MAY REGULATE TRANSCRIPTION OF THE IMATINIB TRANSPORTER HOCT1 EXPRESSION IN CHRONIC MYELOID LEUKAEMIA CELLS	Lihui Wang	Received

977-P	THE ROLE OF CYP2J2 IN CYCLOPHOSPHAMIDE METABOLISM	Ibrahim El-Serafi	Received

978-P	ABCB1 HAPLOTYPE IS ASSOCIATED WITH ALTERATIONS IN FUNCTIONAL ACTIVITY OF P-GP AND AFFECTS MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH STANDARD-DOSE OF IMATINIB	Douglas Vivona	Received

979-P	DIAGNOSTIC AND THERAPEUTIC POTENTIALS OF EXPRESSION LEVELS OF BIOACTIVE SPHINGOLIPID GENES IN NEWLY DIAGNOSED AND DRUG-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS	Yusuf Baran	Received

980-P	SMO INHIBITOR SPECIFICALLY TARGETS THE HEDGEHOG PATHWAY AND REVERTS THE DRUG-RESISTANCE OF LEUKEMIC STEM CELLS	viviana guadagnuolo	Received

983-P	CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA	Kristin MacIntosh	Received

987-P	PULMONARY EFFECTS OF PERFLUOROCARBON EMULSION THERAPY ON INFECTED SICKLE CELL MICE	Nawal Helmi	Received

988-P	THE BTK-SPECIFIC INHIBITOR ONO-4059 SYNERGIZES WITH THE BCL2 INHIBITOR ABT-263.	Martin Dyer	Received

989-P	EFFICIENCY OF CD19 TARGETING BY MONOCLONAL ANTIBODIES IN EX VIVO AND MOUSE MODELS OF CHILDREN ACUTE B-LYMPHOBLASTIC LEUKEMIAS	Arthur Dony	Received

990-P	INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACI) ON CD20 EXPRESSION AND EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES	Malgorzata Wanczyk	Received

991-P	BOTANICAL ALKYL HYDROQUINONE HQ17(3) EXHIBITS CYTOTOXIC EFFECT ON SUP-B15 ALL CELLS HARBORING T(9;22) PHILADELPHIA CHROMOSOME THROUGH INDUCING IRON-DEPENDENT LYSOSOMAL EVENTS AND OXIDATIVE STRESS	Chung-Yi Hu	Received

995-P	THE DONOR DEPENDENT IMMUNE MODULATORY POTENTIAL OF MESENCHYMAL STROML CELL PREPARATIONS CAN BE PREDICTED BY GALECTIN-9	Christopher Ungerer	Received

996-P	INCREASING SAFETY AND EFFICACY OF TCR TRANSFER BY EMPLOYING A MINIMALLY MURINIZED HUMAN TUMOR-REACTIVE SINGLE-CHAIN TCR	Beate Hauptrock	Received

998-P	STAINING OF ANTIGEN-SPECIFIC CD4 T CELLS USING MHC CLASS II TETRAMERS GENERATED ACCORDING TO A NOVEL METHOD OF PEPTIDE-MHC CLASS II MONOMER PRODUCTION AND PURIFICATION	Peter Braendstrup	Received

999-P	PMHC ARRAYS DEMONSTRATE THAT UNTOUCHED T CELL POPULATIONS FROM PRESENTATION ACUTE MYELOID LEUKAEMIA PATIENTS PREDOMINANTLY RECOGNIZE THE CANCER-TESTIS ANTIGEN, PASD1	Barbara Guinn	Received

1000-P	CYTOKINE INDUCED KILLER CELLS ARE ACTIVE AGAINST NON-SMALL CELL LUNG CANCER AND OVERCOME THE ACQUIRED RESISTANCE TO TARGET THERAPIES	Maja Todorovic	Received

1002-P	NATURAL KILLER CELL EXPANSION UNDER GOOD MANUFACTURING PRACTICE CONDITIONS FOR CLINICAL USE IN ADULT PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Nadia Peragine	Received

1003-P	EFFICIENT GENERATION OF HLA-A2 AND A24-RESTRICTED WT1-SPECIFIC CYTOTOXIC T LYMPHOCYTES USING GENE-ENGINEERED ARTIFICIAL ANTIGEN-PRESENTING CELLS	Masahiro Ogasawara	Received

1004-P	OPTIMIZATION OF ALLOGENEIC NK CELLS FOR ADOPTIVE TRANSFER THERAPY	Michal Besser	Received

1007-P	CENTRALIZED PRODUCTION AND DISTRIBUTION OF CMV-SPECIFIC CYTOTOXIC T CELL LYMPHOCYTES	Anke Friedetzky	Received

1008-P	LAK CELLS AND ANTI-CD20 MONOCLONAL ANTIBODIES AS INMUNOTHERAPY ON FOLLICULAR LYMPHOMA: ENCHANCED ANTIBODY-DEPENDENT CELL CITOTOXICITY OF LAK CELLS IN ASSOCIATION WITH GA101 RATHER THAN RITUXIMAB	Alfonso Piérola Ana	Received

1009-P	ROLE OF CIRCULATING &945;&946;-DOUBLE NEGATIVE T CELLS (DNT) IN LYMPHOMA PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY	Giacoma De Tullio	Received

1010-P	EFFECT OF HISTONE METHYLTRANSFERASE EZH2 INHIBITOR 3-DEAZANEPLANOCIN A (DZNEP) ON ERYTHROPOIESIS	Tohru Fujiwara	Received

1011-P	Locus Control Region in the HBB globin cluster: HS3 deletion has a very limited effect over adult globin gene expression	Felix De La Fuente	Received

1013-P	INHIBITION OF ERYTHROPOIESIS THROUGH HEPCIDIN AND ROS IN TRANSFUSION-RELATED IRON OVERLOAD MICE	MASAYOSHI MASUKO	Received

1014-P	CONGENITAL DYSERYTHROPOIETIC ANEMIA DUE TO A NOVEL GATA-1 MUTATION	Janet Pereira	Received

1015-P	EFFECTS OF CHRONIC PSYCHOLOGICAL STRESS ON EXTRAMEDULLARY ERYTHROPOIESIS: INVOLVEMENT OF EPOR, GR, C-KIT AND BMP4 SIGNALING	Mirela Budec	Received

1016-P	DOES THE OPTICAL MICROSCOPE TELL US THE COMPLETE STORY IN MEMBRANE-CYTOSKELETON DISORDERS? A STUDY OF RED BLOOD CELLS WITH ATOMIC-FORCE AND SCANNING-ELECTRON MICROSCOPES IN HEREDITARY SPHEROCYTOSIS	Dimosthenis Stamopoulos	Received

1017-P	INVESTIGATION OF HEMORHEOLOGICAL PARAMETERS AT THE DIAGNOSIS AND THE FOLLOW-UP OF NUTRITIONAL VITAMIN B12 DEFICIENT CHILDREN	Hazal Tancer-Eli	Received

1018-P	X-LINKED SIDEROBLASTIC ANEMIA: A PROMOTER MUTATION IN THE ALAS2 GENE	Janet Pereira	Received

1022-P	IMMUNOGENICITY OF LIPEGFILGRASTIM AND PEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: INTEGRATED ANALYSIS FROM PHASE II AND III STUDIES	Afsaneh Abdolzade-Bavil	Received

1024-P	LIPEGFILGRASTIM A LONG-ACTING, ONCE-PER-CYCLE, GLYCOPEGYLATED RECOMBINANT HUMAN FILGRASTIM CREATED WITH SITE-SPECIFIC GLYCOPEGYLATION TECHNOLOGY	Christian Scheckermann	Received

1025-P	SAFETY AND TOLERABILITY OF LIPEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: AN INTEGRATED ANALYSIS OF PHASE II AND III STUDIES	Oleg Gladkov	Received

1026-P	CARDIAC INVOLVEMENT IN TYPE 3 EGYPTIAN GAUCHER DISEASE PATIENTS: A REPORT OF 7 CASES AND A NEWLY REPORTED ANOMALY	Magy Abdelwahab	Received

1027-P	A FEASIBILITY STUDY OF HOME MONITORING OF BLOOD NEUTROPHIL COUNTS IN PATIENTS WITH CHRONIC NEUTROPENIA	David Dale	Received

1029-P	LANGERHANS CELL HISTEOCYTOSIS (LCH) IN EGYPTIAN CHILDREN. A SINGLE CENTER EXPERIENCE.	Sedky Mohamed Sedky	Received

1030-P	PEGFILGRASTIM AS PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING CHEMOTHERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA	Claudio Cerchione	Received

1031-P	CHRONIC BENIGN NEUTROPENIA IN ADULTS: LABORATORY AND CLINICAL PARAMETERS OF A 6-YEAR FOLLOW-UP	BRUNO FATTIZZO	Received

1034-P	LANGERHANS CELL HISTIOCYTOSIS: ONE CENTER EXPERIENCE BETWEEN 1990-2012	Tulin Tiraje Celkan	Received

1035-P	A NEW TYPE OF CHEDIAK-HIGASHI SYNDROME? CASE REPORT OF A BLACK HAIRED GIRL WITHOUT OCULOCUTANEUS ALBINISM PRESENTED WITH EARLY ONSET HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	Halil Ugur Hatipoglu	Received

1036-P	CHEMOTHERAPY-ASSOCIATED TREATMENT BURDEN IN BREAST CANCER PATIENTS RECEIVING LIPEGFILGRASTIM OR PEGFILGRASTIM: SECONDARY EFFICACY DATA FROM A PHASE III STUDY	Oleg Gladkov	Received

1037-P	USE OF ROMIPLOSTIM IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (CITP) DURING PERI-OPERATIVE PERIOD	William Alexander	Received

1039-P	A MULTICENTER OBSERVATIONAL STUDY FOR EARLY DIAGNOSIS OF GAUCHER DISEASE IN PATIENTS WITH SPLENOMEGALY AND/OR THROMBOCYTOPENIA	Irene Motta	Received

1040-P	A RETROSPECTIVE ANALYSIS OF EPSILON-AMINO-CAPROIC ACID THERAPY IN HYPOPROLIFERATIVE THROMBCYTOPENIA	Shweta Jain	Received

1041-P	THE USE OF MYCOPHENOLATE MOFETIL IN THE TREATMENT OF CHRONIC REFRACTORY IMMUNE THROMBOCYTOPENIA PURPURA	Alice Taylor	Received

1043-P	DURATION OF BLEEDING SYMPTOMS 14 DAYS BEFORE DIAGNOSIS IS A STRONG PREDICTOR FOR DEVELOPMENT OF CHRONICITY IN CHILDHOOD PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)	Andromachi Papagianni	Received

1044-P	PLATELET ACTIVATION MARKERS IN PATIENTS WITH INCREASED CARDIOVASCULAR RISK	Gavriilaki Eleni	Received

1046-P	THROMBOCYTOPENIA PREDICT MORTALITY IN CRITICALLY ILL PATIENTS	Emel Gurkan	Received

1049-P	THE IMMATURE PLATELET FRACTION IS SENSITIVE TO THE PLATELET SIZE AND A USEFUL PARAMETER FOR SCREENING FOR MACROTHROMBOCYTOPENIA	Miyazaki Koji	Received

1052-P	OVERVIEW OF RUSSIAN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) REGISTRY	Igor Lisukov	Received

1053-P	DIFFERENTIAL DIAGNOSIS OF THROMBOTIC MICROANGIOPATHY: DATA FROM PADOVA TTP CASE SERIES	Giulia Berti de Marinis	Received

1055-P	EXTREME THROMBOCYTOSIS ( 1000 X 109 /L) IN 336 PATIENTS- REPORT OF A FOUR-YEAR EXPERIENCE	Emmanouil Papadakis	Received

1056-P	ANTIPLASMIN, BUT NOT AMILORIDE, PREVENTS SYNOVITIS AND CARTILAGE DESTRUCTION FOLLOWING HEMARTHROSIS IN HEMOPHILIC MICE	laurens nieuwenhuizen	Received

1058-P	MOLECULAR DIAGNOSTIC IN 47 UNRELATED FAMILIES WITH HAEMOPHILIA A IN ARAGON (SPAIN)	Silvia Santa Catalina	Received

1059-P	IMPAIRED PROPLATELET FORMATION IN A NOVEL GLANZMANN VARIANT MACROTHROMBOCYTOPENIA	Koji Miyazaki	Received

1060-P	MUTATION ANALYSIS IN TURKISH RARE BLOOD DISORDERS	D&304;DEM TORUN	Received

1062-P	HOW DO WE ENCOUNTER RARE FACTOR DEFICIENCIES IN CHILDREN? SINGLE CENTER RESULTS	Zafer Salcioglu	Received

1066-P	ACQUIRED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY: CLINICAL CHARACTERIZATION AND RECOVERY TO INFUSION OF VWF-CONTAINING CONCENTRATES	Chiara Ambaglio	Received

1067-P	VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN HOSPITALIZED OBSTETRIC PATIENTS : A MULTICENTRE CROSS-SECTIONAL STUDY	Maeve Crowley	Received

1068-P	INVESTIGATION TO IMPROVE DETECTION OF LUPUS ANTICOAGULANT IN A LOCAL POPULATION EXPERIENCING RECURRENT MISCARRIAGE AND INTRAUTERINE DEATH	Ailin McMahon	Received

1070-P	THROMBOSIS IN CHILDHOOD ACUTE LEUKEMIA	yaman yntem	Received

1072-P	ULTRASTRUCTURAL ANALYSES OF THE NOVEL CHIMERIC HEMOSTATIC AGENT GENERATED VIA NANOTECHNOLOGY, ABS NANOHEMOSTAT, AT THE RENAL TISSUE LEVEL	Ibrahim Haznedaroglu	Received

1073-P	MORTALITY OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND RELATION TO COAGULATION AND INFLAMMATORY BIOMARKERS	Shereef Elmoamly	Received

1074-P	EPCR SER219GLY POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA	Sergey Kapustin	Received

1075-P	POLYMORPHISM OF VASCULAR TONE REGULATING GENES AND THE RISK OF VENOUS THROMBOEMBOLISM IN INDIVIDUALS WITH INHERITED THROMBOPHILIA	Anastasia Polyakova	Received

1076-P	PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN PATIENTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA A SYSTEMATIC REVIEW	Mandy Lauw	Received

1077-P	THROMBOPHILIAS INCIDENCE IN PATIENTS WITH FETAL LOSS IN LAST TRIMESTER AND EVALUATION OF THE EFFECTIVENESS OF TREATMENT	LAURA BERMEJO MARTÍNEZ	Received

1079-P	THE NOVEL NOX INHIBITOR 2-ACETYLPHENOTHIAZINE IMPAIRS COLLAGEN-DEPENDENT THROMBUS FORMATION IN A GPVI-DEPENDENT MANNER	Dina Vara	Received

1080-P	COMPARISON OF PATIENTS AND PHYSICIANS PERCEPTIONS OF PATIENTS BASELINE HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Isabelle Vande Broek	Received

1081-P	PROFILING PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES WHO PREFER TO RECEIVE SURVIVAL PROGNOSTIC INFORMATION. FINAL RESULTS FROM A LARGE INTERNATIONAL PROSPECTIVE COHORT OBSERVATIONAL STUDY	Fabio Efficace	Received

1082-P	CROSS-CULTURAL DEVELOPMENT OF AN EORTC QUESTIONNAIRE FOR ASSESSING QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA PATIENTS: THE EORTC QLQ-CML24	Fabio Efficace	Received

1084-P	HOW ACCURATE ARE PHYSICIANS IN ESTIMATING SYMPTOM SEVERITY AND HEALTH STATUS OF THEIR CHRONIC MYELOID LEUKEMIA PATIENTS?	Fabio Efficace	Received

1085-P	PATTERNS OF FATIGUE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER OBSERVATIONAL STUDY	Fabio Efficace	Received

1086-P	PAIN AND EMOTIONAL DISTRESS IN HEMATOLOGIC PATIENTS THROUGHOUT ALL PHASES OF DISEASE: RESULTS FROM A MULTIDISCIPLINARY RESEARCH TEAM IN MODENA UNIVERSITY HOSPITAL	Pierluigi Alfieri	Received

1087-P	EFFICACY OF FENTANYL IN COMPARISON TO KETAMINE IN ANALGESIC EFFECT FOR HEMATOLOGY /ONCOLOGY PROCEDURES IN CHILDREN. A RANDOMIZED, DOUBLE-BLINDED, CROSSOVER, PLACEBO-CONTROLLED TRIAL	chanchai traivaree	Received

1088-P	IS SCREENING FOR MALNUTRITION USEFUL IN OLDER PATIENTS WITH AGGRESSIVE HAEMATOLOGICAL MALIGNANCIES?	Anja Velghe	Received

1089-P	IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN ACUTE MYELOID LEUKEMIA SURVIVORS	Annemieke Leunis	Received

1090-P	VALIDATION OF THE G8 IN OLDER PATIENTS WITH A HAEMATOLOGICAL MALIGNANCY	Anja Velghe	Received

1091-P	PSYCHOLOGICAL ASSESSMENT OF SIBLINGS OF PATIENTS WITH CHILDHOOD CANCER: A FORGOTTEN GROUP	Ragab Iman	Received

1092-P	HEALTH-RELATED QUALITY OF LIFE AMONG LONG-TERM SURVIVORS OF ADOLESCENT HODGKINS LYMPHOMA TREATED WITH PEDIATRIC APPROACH	Sergey Semochkin	Received

1094-P	EARLY SUPPORTIVE/PALLIATIVE CARE INTEGRATED WITH STANDARD HEMATOLOGICAL CARE (SIMULTANEOUS CARE) IN MULTIPLE MYELOMA PATIENTS	FEDERICO VINCENZO	Received

1095-P	WHAT DO PRELIMINARY ANALYSES HIGHLIGHT AS THE KEY FEARS AND WORRIES OF CHILDREN AND YOUNG PEOPLE WITH SICKLE CELL DISEASE AND WHAT CAN WE DO TO SUPPORT THEM?	Florence Bristow	Received

1096-P	COMPREHENSIVE ANALYSIS OF CLINICALLY RELEVANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN HEMATOLOGIC MALIGNANCY FROM THE VIEWPOINT OF REVISED EMAS GUIDELINE ON ANTICANCER MEDICINAL PRODUCTS	Sumimasa Nagai	Received

1097-P	DOES PREGNANCY INFLUENCE REMISSION RATE IN HEMATOLOGICAL MALIGNANCIES	Maria Vinogradova	Received

1098-P	VALIDATION OF A COMPREHENSIVE HEALTH STATUS ASSESSMENT SCALE IN OLDER PATIENTS (= 65 YEARS) WITH HEMATOLOGICAL MALIGNANCES. GAH STUDY	Cristina Romera	Received

1099-P	PSYCHOLOGICAL MORBIDITY FOLLOWING THE DIAGNOSIS OF A HAEMATOLOGICAL MALIGNANCY	Barry Kevane	Received

1100-P	QUALITY OF LIFE OF THE PATIENTS WITH HEMATOLOGICAL MALIGNANCIES	LIUDMILA GRITSAY	Received

18th Congress of EHA

13-16 June 2013 STOCKHOLM

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 13/06/2013 TO 16/06/2018

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.18eha.2013



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access